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Abstract 
 
 
Ruminants possess a unique digestive system.  Using the high metabolic potential 
of the symbiotic microflora of the rumen, ruminants are capable of digesting plant 
material and obtaining nutrients and energy from this process.  Because of the 
ruminal fermentation, the most bioactives are not stable in the harsh ruminal 
environment.  Therefore there is a need to improve the bioavailability of a 
bioactive by protecting it from the ruminal digestion.  The formulation of 
protected bioactive can be delivered in the rumen in a controlled manner and over 
a long period of time. 
In this project the degree of rumen protection was estimated using model 
substrates (sugar pellets and granules).  These materials were coated with the   
pH-sensitive polymer Eudragit® E.  The model bioactive (phloridizin) was coated 
using the coating methodology adopted from exploratory studies with model 
substrates.  The bioavailability of “protected” (coated) phloridizin was assessed by 
administering directly into the abomasum of fistulated cows.  
Formulation of “protected” phloridizin was used to demonstrate the feasibility of 
bioactive controlled delivery based on ART (“Active Rumen Technology”).  This 
technology uses an elevated gas pressure created by a hydrogen-producing cell to 
drive a plunger which extrudes bioactive formulation from an intraruminal 
controlled-release device. 
Four groups of devices filled with formulation containing different amounts of 
“protected” phloridizin were tested.  The bioactive was released in a controlled 
manner over several days.  The formulation release profiles were reproducible 
suggesting that in principle the technology can be further developed to use in a 
commercial sense or for research purposes.  The limitations of the technology, 
including formulation issues and gas diffusion through barrel walls, were 
identified. 
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1.1 Background and information 
The generally moderate climate in New Zealand allows pastoral farming almost 
the whole year around.  There is a very vibrant agricultural industry in which 
ruminant animals such as cattle, sheep and goats play an important part.  As such, 
animals significantly contribute to the country’s economy. 
New Zealand is one of the world's largest exporters of dairy products (Dairy 
industry profile 2005).  In the year to June 2007, dairy products were New 
Zealand’s largest export earners and accounted for 21% (NZ$7.5 billion).  Other 
animal products such as meat and wool (13.2% and 6.3% of total merchandise 
exports respectively) also significantly contribute to overall country’s export 
(New Zealand External Trade Statistics 2007). 
In 2007, national live-stock numbers were 9.7 million cattle and 38.6 million 
sheep (Ministry of Agriculture and Forestry 2008).  It is therefore important to 
ensure good animal health and well-being.  All possible measures towards 
improving the live-stock status will greatly increase animal productivity resulting 
in lower production end-costs.  
Pharmaceutical science possesses considerable knowledge to effectively treat 
animals.  The properties of pharmaceuticals in terms of safety, efficacy and costs 
are being constantly being improved and delivery of bioactives is being 
optimized.  There is a continuing need for long-term delivery systems for 
bioactives so animal health and productivity is improved. 
Many factors must be considered when developing a bioactive dosage form for 
ruminants.  The most significant include cost, convenience and frequency of 
administration.  Repeated administration to a large number of grazing animals is 
very labour-intense and expensive.  Other issues include tissue residues and 
environmental and handler safety.  Finally, in developing rumen dosage forms, the 
harsh environment of the ruminant digestive system has to be considered.  
Developing a novel bioactive delivery system, which ideally meets all the 
requirements described while releasing a rumen-protected bioactive in a 
controlled manner and over the required time is the subject of this project.  
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1.2 Project objectives 
The goals of the project are: 
• to protect the model bioactive PHZ (phloridizin) against ruminal 
degradation by coating it with the polymer Eudragit® E.   
• to deliver the rumen-protected bioactive using “Active Rumen Technology” 
(ART), which uses an elevated gas pressure created by a hydrogen 
producing cell to drive a plunger which extrudes bioactive formulation. 
 
The milestones to achieve these goals are: 
 
• develop a reliable and effective pan coating method using sugar particles as 
a model substrate 
• manufacture rumen protected model bioactive PHZ (phloridizin) using the 
developed coating procedure 
•  assess the degree of (probable) “rumen protection” of coated model 
bioactive in vitro 
• assess the degree of rumen protection of coated model bioactive in vivo 
• deliver the rumen protected bioactive using ART 
• identify advantages and constraints in the rumen protected delivery system 
 
1.3 Thesis structure 
Chapter 2 reviews diseases of live-stock, challenges that arise in therapy of 
ruminants, and different pharmaceutical approaches in medicating ruminants 
including rumen controlled-release devices.  The digestive system of ruminants 
and some approaches to protect bioactives against ruminal environment are 
described.  A brief review of coating technology and the model bioactive 
phloridizin are given.  
The materials used are described in Chapter 3 along with descriptions of the pan 
coating process, the methods used to assess coated sugar and PHZ particles, and 
studies on release of coated PHZ particles using a rumen controlled-release 
device.   
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Chapter 4 has the results and discussion on characterizing the coating process, the 
characteristics of coated particles, their in vitro and vivo assessment and their in 
vitro delivery using a rumen controlled-release device.  
The conclusions and recommendations are presented in Chapter 5. 
Raw data is summarized in the appendices. 
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2.1 Special features of ruminant health care 
Like humans, animals need supplementary nutrients and pharmaceuticals that help 
to maintain good health and prevent or combat diseases.  While the medication of 
humans is aimed to improve quality of live, intervention with bioactives in 
ruminants is primarily aimed to increase their production.  Thus, all the 
approaches in medication and/or supplementation using bioactives or feed 
additives to ruminants have an economical motivation. 
The factors that can influence the animal production include: 
• Nutritional deficiency 
• Infectious diseases  
• Parasites (internal and external) 
• Metabolic disorders 
• Controlling reproduction  
• Manipulating animal growth 
Nutritional deficiency 
Ruminants need nutrients such as vitamins and microelements for their optimal 
growth and performance.  However, in contrast to humans, ruminants are 
dependent on obtaining microelements from the specific grazing area, which can 
be deficient in microelements such as cobalt, copper, zinc, iodine etc.  To 
compensate this deficiency the animals would need to be shifted to another 
grazing area.  This way of compensating deficiency in livestock is, in most cases, 
economically irrational, therefore nutrients need to be supplied to the animal.  
Infectious diseases 
A variety of microorganisms including viruses, bacteria, protozoa and fungi can 
affect the animal, interfere with its metabolism and, if untreated, cause severe 
pathological conditions.  The most common infections of ruminants comprise 
those of the digestive tract, reproductive organs and open wounds. 
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Parasites (internal and external) 
Internal parasites such as helminths are major production limiting factors for 
ruminants.  While therapy with anthelminthic vaccines is promising but at the 
present not applicable, the anthelminthic gene therapy is still a futuristic vision.   
Despite the development of anti-drug resistance in the parasite, classical 
chemotherapy is still the only effective option of treating infections with 
helminths. Some effective approaches of anthelminthic therapy of ruminants 
including Captec controlled-release system are described in section 2.4. 
A variety of external parasites such as insects, ticks, and mites affect the well-
being and productivity of livestock.  These parasites can cause blood loss, 
increase the chance of an infectious disease, or transmit diseases.  Irritation of the 
animal caused by ectoparasites can interfere with feeding and resting patterns, 
resulting in reduced feed conversion efficiency, reduced weight gains, decreased 
milk production and decreased wool production.  In some cases, damage caused 
by ectoparasites can decrease the value of hides and carcasses (Miller 2000).   
Metabolic disorders 
Because many different factors (e. g. changed feed composition) can induce 
metabolic deviations associated with different symptoms, there are not sufficient 
commercial products to suit the needs individually.  Examples of metabolic 
disorders of dairy cattle are bloat, and ketosis and acidosis. 
Bloat occurs mostly when animals are fed with high-quality fodder such as 
lucerne, medics, clover etc, which induce intraruminal production of large 
volumes of gases such as methane and stable foams.  The inability of the animal 
to eructate more rapidly than the gas accumulates can produce high intraruminal 
gas pressure, which can lead to closure of major blood vessels and obstruction of 
inner organs (Vandamme and Ellis 2004).  To prevent the foam establishing, some 
effective surfactants such as Pluronic® PE 6200 can be orally administered 
(Commercial product Bloat Guard®) (Agrimin Ltd., Undated).  Some foam de-
stabilizing agents can also be delivered with other bioactives from a rumen 
controlled-release dosage form.  
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Another metabolic disorder that implies pathological increase of acid and ketotic 
substances can be caused by forage being too acidic.  This results in the buffering 
capacity of the rumen being over-ridden and the normal ruminal microflora being 
destroyed.  The antibiotic momensin in Rumensin® ABC intraruminal bolus 
partially inhibits growth of bacteria involved in acetate and propionate production 
and restores the physiological pH-balance. 
Controlling reproduction 
It is of great importance to accurately control the reproductive cycle of the cattle.  
This can be achieved by manipulating the oestrus of selected female animals in a 
herd by means of hormones.  The selected animals can be inseminated at the same 
time (Burns 1999).  This results in  shorter lactation-free intervals and therefore  
to increase in milk yields (Rathbone et al. 1997). 
Manipulating animal growth  
Delivering growth promoters to food-chain animals is a direct approach to 
increasing their productivity.  An overview of different pharmaceutical 
approaches to deliver growth-promoters to cattle is given in the section 2.2.1. 
 
2.2 Controlled-release systems for ruminants 
Some principles of design and function of veterinary controlled-delivery systems 
were adopted from those for human medicine.  However, besides the more 
obvious differences in anatomy and physiology, there are several factors such as 
cost, convenience and safety that result in the need to have different approaches 
when developing controlled-release systems for veterinary use.   
The following four major groups of controlled-released delivery systems for 
livestock are: 
• Injectable and implantable systems 
• External attachments  
• Intravaginal  inserts 
• Intraruminal dosage forms 
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2.2.1 Injectable and implantable systems 
Injectable and implantable systems represent a practical dosage form for use in 
animals.  The delivery of these parenteral dosage forms requires less labour 
associated with bioactive administration than conventional immediate-release 
bioactive delivery.  
One of the simplest sustained release injectable systems is a long-lasting 
formulation of the antibiotic oxytetracycline used by Pfizer for treating pasteurella 
pneumonia in cattle.  Compared with conventional injection, efficacious blood 
levels of oxytetracycline, released from this formulation, stay almost twice as long 
(Cardinal and Witchey-Lakshmanan 1992).   
 Another example for an injectable controlled-release is an intramuscular delivery 
of testosterone propionate.  If delivered in crystals the effect lasts over 8-12 days, 
and if delivered in oil solution, for 3-9 days.  A subcutaneous injection of 
testosterone propionate pellets is effective over 4-5 weeks (Sinkub 1978).    
Another injectable product, Ivomec®  contains the anthelmintic bioactive 
ivermectin, which is dispersed in propyleneglycol and glycerol formal (Merial 
product information 2006).  Long half-life of ivermectin and the nature of the 
formulation contribute to a prolonged therapeutical effect and necessities only 
once a month administration.  
Implantable systems have been successfully used for promoting growth in cattle.  
For example, Synovex® S and H (Fort Dodge Animal Health, Kansas, USA),  
marketed by Syntax to use in steers, release estradiol benzoate/progesterone and 
estradiol benzoate/testosterone propionate respectively (Cardinal and Witchey-
Lakshmanan 1992). 
Subcutaneous ear-implants such as Syncro-MATE-B® and SYNCRO-MATE-
C®(CEVA, Libourne,France) have been developed for cattle and contain the  
hormone (norgestomet).  Another subcutaneous ear-implant is Melovine® 
(CEVA) that delivers hormone melatonin to sheep. 
An oestrogen containing system COMPUDOSE® (Elanco Animal Health, 
Indianapolis, IN, USA) (Lewis 1995) consists of a drug-free silastic cylinder 
Chapter 2: Delivering Bioactives To Ruminants 
 
10 
coated with a layer of silicone rubber containing 20 % estradiol-17b.  In order to 
minimize the chances of infection at the site of implantation the dosage from is 
coated with a small amount of oxytetracycline hydrochloride (Ferguson 1988).      
COMPUDOSE® has the advantage of giving a more linear release profile due to a 
thin bioactive layer containing high amount of dispersed bioactive. 
2.2.2 External attachments  
External controlled delivery systems for livestock are aimed to deliver pesticides 
over time to repel insects that affect productivity (Miller 2000).  These delivery 
systems can be applied to cattle as ear tags and collars.  An example is the 
Atroban® Eartag (Schering-Plough Animal Health) (Atroban, Product 
information, Undated), which releases permethrin for a period of three months. 
The monolithic structure  of  many currently available ear tags is responsible for 
an initially high release rate, which decreases over the time, and can lead to 
development of resistance against the insecticide due to a prolonged exposure of 
sublethal insecticide doses (Baggot 1988).  To improve the release profiles Herbig 
et al. have developed a membrane-based ear tag that releases insecticide at a 
constant rate over required period of time (Herbig and Smith 1988).   The release 
of insecticide is determined by the permeability and geometrical parameters of the 
membrane.  Further examples for external attachment are neckband systems 
which have been developed for the controlled delivery of organophosphorous 
insecticides to cattle (Miller and Oehler 1988).  
2.2.3 Intravaginal inserts 
The benefits of intravaginal bioactive delivery include avoidance of tissue damage 
that is often associated with injections, and a less stressful administration for the 
animal.  A further advantage is the possibility of interrupting the therapeutic effect 
by withdrawal of an intravaginal dosage form. 
 
A number of intravaginal veterinary bioactive delivery systems have been 
marketed.  These include CIDR® (InterAg, Hamilton, New Zealand), intravaginal 
polyurethane sponges of various sizes and densities (Figure 1), and PRID 
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(Progesterone-Releasing Intravaginal Device) (CEVA, Libourne, France)    
(Figure 2) (Eichman 1999). 
 
Controlled Internal Drug Release dispensers (CIDR®) are intravaginal T-shaped 
devices constructed of a progesterone-impregnated medical silicone elastomer 
molded over a nylon core (Bunt et al. 1999).  The devices were designed for 
different types of production animals (Figure 1).  The winged form of CIDR® 
devices to facilitate intravaginal retention, resembles some intraruminal devices  
(section 2.4.1). 
 
Figure 1: Commercially available oestrus-synchronizing controlled release 
intravaginal drug delivery systems 
CIDR-S® (sheep); (b) CIDR-G® (sheep and goats); (c) CIDR-B® (cattle) (InterAg, Hamilton, 
New Zealand); (d) Repromap® sponge (sheep) (from Rothen-Weinhold et al. 2000). 
 
 
Intravaginal sponges are cylindrical-shaped polyurethane sponges impregnated 
with varying quantities of synthetic progestogens. Syncro-Part®  and Syncro-
Part® MSG (pregnant mares serum gonadotrophin, CEVA) were designed for 
sheep and cattle, respectively. 
 
The Progesterone-Releasing Intravaginal Device (PRID®, CEVA, Libourne, 
France) was the first commercially available intravaginal delivery system and was 
originally developed for use in cattle (Rothen-Weinhold et al. 2000). It comprises 
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micronized progesterone uniformly suspended in an elastomeric silicone matrix.  
Auxiliary components of the system are gelatin capsule containing oestardiol 
benzoate and a string to facilitate removal (Figure 2). 
 
Figure 2: Progesterone-releasing intravaginal device (PRID®) (cattle) 
(from  Rothen-Weinhold et al. 2000). 
2.2.4 Intraruminal dosage forms  
These dosage forms are described in detail in section 2.4. 
2.3 The digestive tract of ruminants 
Ruminants are herbivores with a unique digestive system adapted to splitting the 
cellulose in plant structures, thereby making more of the plant components 
available for use by the host animal.  This is achieved by a combination of 
structural/anatomical features, and the symbiotic relationship with a variety of 
microflora. 
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The main anatomical difference from monogastric animals is that ruminant 
stomach has four distinct compartments: reticulum, rumen, omasum and 
abomasum (Figures 1 and 2).  
 
Figure 3: Gastro-intestinal tract of cattle  
(Vandamme and Ellis 2004). 
 
 
 
 
Figure 4: Diagram of the reticulorumen. 
ABO, abomasum; OM, omasum; CSR, cranial sac; RET, reticulum; D, duodenum; ROO, reticulo-
omasal orifice (from Wu and Papas 1997). 
The first and largest is the reticulo-rumen, with a volume of 100 to 225 L in full-
grown cattle and 10–25 L in ovine and caprine species (Vandamme and Ellis 
2004).  In this compartment ingested feed is mixed with water and saliva, and 
exposed to the rumen microbes, whose main role is to break down the cellular 
components of the feed and release nutrients.  There is continual turbulence that 
ensures good mixing, provides for some fractionation of particular matter, and 
promotes in a very complex way for the initiation of rumination (see below).  
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Cattle produce about 100-190 L of saliva per day (Silanikove 1992).  Continuous 
inflow provides extra fluid for the fermentation and a strong pH buffering of the 
digesta to optimise the microbial activity.  
Rumination is the repeated regurgitation (initiated by ruminal motion and 
responses) of ingesta from the reticulum, followed by re-mastication and re-
swallowing.  It provides extra mechanical breakdown of roughage, increasing 
substrate surface area available to the fermentation microflora.  The rumen 
environment is a unique ecosystem which supports three major types of micro-
organisms: bacteria, protozoa and fungi.  It is a suitable environment for 
establishing continuous fermentation because:  
• The temperature is relatively constant (approximately 39°C).  
• Physical conditions such as pH (6.5–7.0) and osmotic pressure  
(260–340 mOsm) (Merchen and Hubert 2002) are relatively stable.  
• The host animal provides a regular, continuous supply of substrate.  
• Fermentation end-products are continuously removed by soluble material 
being absorbed across the ruminal epithelia and undigested material being 
expelled to the rest of the digestive system.  This prevents end-products 
accumulating and inhibiting microflora activity.  
• Gases such as carbon dioxide, methane, nitrogen (65%, 27% and 7% 
respectively) and trace amounts of hydrogen and hydrogen sulphide  
produced in the rumen are expelled by eructation (McArthur and Miltimore 
1961).  Adult cattle can produce up to 600 L of ruminal gases (Cardinal 
1997). 
 
The total number of microbes in rumen contents ranges from 1010 - 1012 cells g−1 
(Santos and Huber 2002).  The primary aim of these microbes is to pre-digest the 
plant material yielding short chain volatile fatty acids (VFA) which is the source 
of energy for the microbes and the host animal. Inactive microbial mass passes to 
the abomasum where it is digested by host animal’s enzymatic system.  This 
process yields a pool of amino acids and short peptides which are utilized by the 
host animal (Pell et al. 2000).  Approximately 3 kg/day of microbial protein is 
produced by lactating cows (Herrera-Saldana et al. 1990). 
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Particles greater than 2 mm (cattle) or 1 mm (sheep) tend to be excluded from 
passage through the reticular-omasal orifice; this material is recycled through the 
rumination process.   
The abomasum is a true, glandular stomach, which secretes acid and functions in 
as a manner similar to the stomach of a monogastric.  Ingesta are finally subjected 
to the ruminant’s own digestive enzymes (Harfoot 1978). 
 
2.4 Intraruminal bioactive delivery 
The delivery of pharmaceutical or nutrient supplements to livestock present 
several challenges different from those associated with either humans or with 
other monogastric animals.  At the same time, the rumen offers unique 
opportunities and advantages: 
• Cost/benefit ratio: grazing animals cannot always be mustered for bioactive 
administration over the entire grazing season at the most (drug related) 
beneficial time – long acting delivery systems are therefore required. 
• Longevity of application: properly designed devices can remain in the 
rumen over required (extended) time period. 
• Compliance: the host animal apparently does not recognize the presence of a 
intraruminal device in the rumen.  
• Regular mixing of the rumen contents and the presence of vast amount of 
water.  This facilitates disintegration of the intraruminal device and 
dissolution of the bioactive. 
• Opportunities to use the ruminal microflora to convert a bioactive precursor 
(pro-bioactive) into a more potent derivative.  
• Easier oral administration of intraruminal devices compared with to 
injectables. 
 
On the other hand, when designing any intraruminal device, one has to consider 
following issues: 
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• Bacterial fermentation: the formulation or/and the bioactive can be degraded 
by ruminal microflora. 
• Regurgitation: due to regurgitation the intraruminal device can be propelled 
into the oral cavity and expelled. 
• Dilution factor: due to the large rumen volume and water content the 
bioactive has to be either very potent or be administered in larger amounts. 
• Monitoring of the intraruminal device: the device has to function reliably as 
its monitoring in most cases is not feasible. 
2.4.1 Intraruminal devices 
Intraruminal devices are solid preparations that deliver the bioactive at required 
release rate and over required period of time.  There are several main design 
features that are required for any intraruminal devices: 
• A size and shape making them capable of being readily administered orally.  
• Reliability of long term retention in the rumen. 
• A controlled and long term release of the bioactive. 
Theoretically there should be no limit to the duration of retention and release, but 
in practice the device lifetime should match the health condition for which it is 
designed.  For example, treating an infection might need only days or weeks of 
exposure, an antiparasite drug might be needed for the duration of the grazing 
season, while a nutrient might be needed for 365 days a year.  In practice, most 
current commercial products have a lifetime of around 100 days, and another 
device is re-administered if longer term treatment is required. Some intraruminal 
devices are presented in Table 1. 
Table 1: Some marketed intraruminal devices 
(from Rothen-Weinhold et al. 2000). 
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2.4.2 Ruminal retention 
To avoid regurgitation during rumination, intraruminal devices have to be 
properly designed.  This can generally be achieved either by increasing the density 
(high density devices) or modifying geometrical parameters of the device 
(expanding devices) (Table 1).  Both approaches can also be combined in a single 
device. 
2.4.3 Bioactive release mechanism 
Various physical and/or chemical processes can be used to release the bioactive 
from ruminal devices.  The simplest mechanism is the erosion of a bolus due to 
the permanent agitation of the ruminal contents.  Another approach uses simple 
diffusion of a water-soluble bioactive out of the matrix, while an even more 
sophisticated process relies on osmosis as the release controlling process.  All of 
these types of device can be referred to as “passive” release systems.  On the other 
hand, there are “active” release mechanisms whereby some force is generated to 
mechanically force bioactive from the device.  
 Passive release  
The intraruminal devices that release the active ingredient in passive manner tend 
to be the simplest and the cheapest.  These combine the active ingredient into 
formulation that can determine the release pattern of a bioactive and which can 
give the intraruminal device the required properties of appropriate density and/or 
geometry.  
 
One of the earliest approaches using physical disintegration of an intraruminal 
device was done using iron oxide as matrix with incorporated elemental selenium  
 or cobalt (Dewey et al. 1958).  Similarly minerals and vitamins can be 
incorporated into silicate glasses (Telfer et al. 1984) that disintegrate in the rumen 
over the time and slowly release the bioactive.  Other examples of passive heavy 
density devices are Agrimin® Rumbul (Hemingway and Ritchie 1969) and 
SireSine® magnesium capsule (Ridley, Australasia) (Laby 1973). 
Both consist of a magnesium alloy.  Release occurs not because of abrasion but 
because of electrochemical activity.  In the Ridley product, two half cylinders 
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made of magnesium and aluminium alloy are connected by a rubber hinge.  The 
device is administered in form of the cylinder but when in the rumen the device 
unfolds ensuring ruminal retention by both density and variable geometry.  
More complex are intraruminal devices that combine a bioactive with inert and 
ruminally stable matrix, but in such a way that the matrix material determines the 
release rate of the bioactive from the device.  One of the marketed intraruminal 
devices uses this concept is Paratect Flex® bolus (Pfizer Inc.).  This device is a 
trilaminate sheet that is administered in a rolled shape but once in the rumen the 
rolled sheet uncoils providing retention in the rumen (Ranade and Curtis 1992, 
1994) (Figure 5).  The bioactive morantel is delivered through perforation in the 
sheet consisting of 50:50 ratio of bioactive and ethylene vinyl acetate (EVAc) 
(Brewer and Griffin 1980; Boettner and Aguiar 1988). 
                
 
 
 
 
 
 
 
 
Figure 5: Diagram of Paratect Flex® bolus in a rolled and unrolled shape 
(from Boettner and Aguiar 1988). 
 
The efficacy of some drugs (e.g. anthelmintics, antibiotics) can be improved by a 
pulsed dosing regime.  There are several products that use this strategy. 
The Holloway (Holloway 1982) device has a series of bioactive compartments 
separated by degradable cellulose segments.  Once in the ruminal environment, 
the cellulose segments are degraded by ruminal microflora, which result in the 
adjacent bioactive compartments dissolving.  The duration of the pulse can be 
modulated by the thickness of the cellulose compartments.  In the Vandamme 
development (Figure 6) the drug compartments are separated by biodegradable 
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monofilaments. The duration between pulses depends on the nature of 
microfilaments. 
The Castex system (Figure 7) marketed as Autoworm® or Synanthic Multidose® 
130 (Synthex, Janssen Pharmaceutica) and Repidose® (Coopers) has a central 
magnesium alloy core with five surrounding rings of oxfendazole formulation 
encased in PVC caps.  When exposed to ruminal environment, electrolysis causes 
sequential disintegration of the core which releases the drug tablets.  
 
 
                   
 
 
 
Figure 6: Cross-section of the  
intermittent system of Vandamme  
(from Vandamme and Ellis 2004). 
 
      
 
 
Figure 7: Castex system 
(from Vandamme and Ellis 2004). 
 
A feature of passive release devices is that they have a great dependency on the 
rumen environment, and therefore are prone to variable release, depending on the 
animal’s grazing pattern. 
Active release 
From this type of intraruminal devices the bioactive is released mechanically by 
either a flexible membrane or a plunger driven by some mechanical force, 
commonly either osmotic, spring or gas driven.  Although the bioactive release of 
the devices can sometimes depend on the parameters of the ruminal environment, 
there are inherently more reliable as regards inter-animal and intraruminal 
variations.  
Chapter 2: Delivering Bioactives To Ruminants 
 
20 
The Laby spring driven system (Figure 8) (Laby 1974) was commercialized by 
Elanco in their Rumensin® ABC devices and by Captec (Nufarm Pty., N.Z.) for a 
variety of products.  
The Rumensin® ABC device consists of a solid matrix core of formulation 
contained in a plastic cylinder.  The formulation is a dispersion of surfactant mix 
containing the polyether antibiotic monensin sodium for the treatment of bloat and 
for the enhanced rate of growth.  When in the rumen, the formulation absorbs 
water and softens so the formulation can be released through an orifice under the 
influence of the spring. The device is retained in the rumen by means of an 
expanding pair of plastic wings. 
 
 
 
Figure 8:  Laby spring driven system.  The wings are held in place by a piece 
of tape during administration and passage down the esophagus 
(from Cardinal 2000). 
 
The Captec technology differs only by using a series of tablets instead of a single 
core of formulation used by Elanco (Laby 1987).  This makes possible to vary 
bioactives and their dose to provide pulsed delivery. 
The Ivomec® SR Bolus uses the osmotic technology originally developed by Alza 
(Mountain View, CA, USA) for the Oros ® and Alzet® mini pumps.  This device 
consists of three elements combined in one capsule: a reservoir consisting of 
osmotic ingredient dispersed in a gel, an adjacent reservoir separated by an inert 
flexible membrane, and a density element (Figure 9).  When in the rumen, water 
diffuses across the semipermeable membrane.  The osmotic gel formulation 
increases in volume, which causes the bioactive formulation to be extruded 
through the delivery orifice.  Another example of an osmotic rumen bolus is  
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Dura SE® which delivers sodium selenite to selenium-deficient cattle for up to 
four months (Rothen-Weinhold et al. 2000).  A major disadvantage of the 
technology is its limitation due to the low bioactive pay-load.  Therefore, only 
highly potent bioactives can be used.  
 
Figure 9: Cross-section of the ruminal delivery system Ivomec® SR Bolus  
(from Vandamme and Ellis 2004).  
2.4.4 Controlled bioactive delivery using ART  
Not yet commercially available, but central to this thesis is another plunger driven 
system, ART (Active Rumen Technology).  It uses a galvanic cell to release  up to 
160 mL of hydrogen (Simatec gas-cell product information, Undated).  Elevated 
pressure resulted causes the plunger to extrude bioactive formulation.  Previous 
work (McLellan 2007) has demonstrated the feasibility of linear and reproducible 
release of placebo formulation out of an ART device over an extended period of 
time.  
The first commercialized medical controlled-release system using elevated gas 
pressure of a hydrogen producing cell was the Theratron® (Fresenius) infusion 
system which is made of a syringe that injects up to 60 mL of an infusion liquid 
(Winsel 1993; Winsel and Sauer 2000) . Another example using this approach is 
an injection-moulded intravaginal device that delivers to cattle over 8 days 
(Rathbone et al. 2002; Ismail 2006) and could also deliver a pulse of a second 
bioactive at a predetermined time when a second reservoir of formulation was 
forced open by plunger movement. 
The Active Rumen Technology may have a number of advantages over existing 
controlled-release technologies:  
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• The gas cell occupies a very small volume in the device so a larger bioactive 
payload is possible.  
• Gas production rate is independent of the ruminal environment.  
• There is a potential to modulate the bioactive release rate by remote control.  
 
2.5 Ruminal protection 
Rumen fermentation can destroy or modify bioactives and many drug delivery 
systems used to prevent or treat diseases or increase of livestock productivity.  As 
a consequence, there is a need for a rumen-stable delivery system with the 
capability of delivering rumen protected bioactives.  This will increase efficacy 
and economics because less bioactive would be required.  Initial efforts to develop 
ruminal protection were focused on protecting proteins and amino acids to 
supplement normal animal feeds.   
Chemical treatment 
Chemically treating protein can decrease its solubility and thus increase the 
amount of protein that by-passes the ruminal fermentation process.  Several 
chemical agents have been evaluated including: aldehydes, acetic acid and tannins 
(Ames and Robeson 1976; Vicini et al. 1983).  Another approach is to synthesise 
analogues that are considerably less soluble than the original molecules (Papas et 
al. 1974).   
In a further approach, the pH difference between reticulo-rumen and abomasum 
was used.  While being relatively inert in the ruminal environment, copper oxide, 
after having passed into the abomasum, can be trapped in the abomasal rugae 
where it slowly dissolves delivering biological active copper ions (Vandamme and 
Ellis 2004).   
Heat treatment 
Heat treatment can promote a reaction between amino acids and carbohydrates in 
feed stuffs, reducing rumen degradation rates.  
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Lipid-based formulations 
Formulating small pellets of bioactive that are coated with inexpensive food-grade 
lipid can partially protect the bioactive from degradation in the rumen.  However, 
major limitations of this technology result from the low (ca. 30%) bioactive 
payload that can be routinely achieved, and from the relatively low post ruminal 
absorption rates of these materials.  Despite the disadvantages, several lipid-based, 
rumen protected products are available.  One example is Mepron®, which is 85% 
DL-methionine protected by a fat-fibre-ash coating.  This product can provide 
85% protection of the DL-methionine payload after 5–6 h of rumen incubation 
(Degussa 1995). 
pH-sensitive enteric coating 
An elegant approach to developing a rumen-stable delivery system is using a pH-
sensitive polymer which is stable at rumen pH but which dissolves quickly at 
lower pH values. 
 
2.6 pH-sensitive coating for ruminal drug delivery 
2.6.1 Physiological considerations 
Ingested feed material may be retained, on average for 6 h (and up to ~18 h) in the 
rumen and for approximately 30 min in the abomasum before it is transported into 
intestine.  The pH of rumen fluid is normally 6.5–7.0 and that of abomasal fluid is 
variable but often 2.0–3.0.  This pH difference is the basis for developing a pH-
dependent rumen-stable delivery system.   
2.6.2 pH-sensitive polymers 
The pH-sensitive polymers for coating bioactives that will be used in ruminants 
need to have the following properties:  
• Insoluble in rumen fluid, but soluble in abomasal fluid 
• Physiologically inert, non-absorbable 
• Thermally stable or non-degradable at temperatures used during process and 
storage. 
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A more effective delivery system was developed using copolymers of vinyl 
pyridine and styrene (reverse-enteric coating system) (Eastman Chemical 
Company, Undated).  The coating used a basic polymer such as poly (2-
vinylpyridine–co-styrene in ratio 80:20) (2VP–ST, 80:20).  Methionine and 
glucose pellets were coated in a fluidized bed.  Protection of coated pellets in vitro 
was assessed using simulated rumen fluid pH 5.4 buffer for 24 h followed by pH 
2.9 buffer for 1 h to simulate release in the abomasums (Figure 10).  
 
 
Figure 10: In vitro rumen protection (pH 5.4) and abomasal release (pH 2.9) 
of reverse-enteric protected methionine and glucose pellets  
(from Wu and Papas 1997).  
Further studies have investigated different coating materials.  A study at Kyushu 
University (Yoshimaru et al. 1999) used a methacrylate copolymer Eudragit E® 
100.  This commercial pH-sensitive copolymer has potential for ruminal 
protection.  Porous starch was used as core material to produce 20-30 µm 
microcapsules, which were separately coated with Eudragit® E 100, Aqoat® AS-
HF (Shin-Etsu) and shellac.  In vitro dissolution assays showed that the 
microcapsules were stable in pH 6.5 phosphate buffer and that 85 % of the 
contents were released over 30 min in pH 3 the citrate buffer.  Incubating the 
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particles with ruminal microorganisms showed that the particles had 65% 
protection.  
2.6.3 Eudragit® E 
Eudragit® E ("Basic butylated methacrylate copolymer" Ph. Eur.) is a pH-
sensitive film coating material which has been used in various pharmaceutical 
products since 1959 (Roehm GmbH, Darmstadt, Germany).  
This cationic copolymer (~150,000 Da) is based on dimethylaminoethyl 
methacrylate and neutral methacrylic esters (Figure 11) and is commercially 
available in following forms: 
• Eudragit® E 100 - pellets 
• Eudragit® E PO – powder obtained from Eudragit® E 100 
• Eudragit® E 12,5 – solution of Eudragit® E 100 with 12.5% (w/w) dry 
substance in 60% (w/w) isopropyl alcohol  
 
Figure 11: Chemical structure of Eudragit® E monomer. 
 
Eudragit® E 100 is soluble in methanol, ethanol, isopropyl alcohol, acetone, ethyl 
acetate, methylene chloride (about 1 part of polymer in 7 parts of the solvent) and 
practically insoluble in petroleum ether and water. The most important feature of 
Eudragit® E that is relevant to this project is its pH dependent solubility. The 
polymer is easily soluble under pH 3 but stable at pH values higher than six. This 
can be used to protect bioactives from ruminal degradation by film coating with 
the Eudrgit® E polymer.  
Toxicological studies with Eudragit® E proved its safety (Degussa 2004). 
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2.7 Coating bioactives  
Initially, the coating process was used to preserve food but later on it was used to 
mask the taste of medicines. In 1953, a dramatic change was made in tablet 
coating when Abbott Laboratories marketed the first film-coated pharmaceutical 
product (Wurster 1953).  This initiated interest in using polymers to physically or 
chemically protect the bioactive and/or modify its release. 
There are several major reasons for coating the bioactive:  
• to protect from the environment of the digestive tract with an appropriate 
pH-sensitive polymer 
• to provide physical and chemical protection 
• to control the release  
• to incorporate another bioactive or excipient in the coating to avoid 
chemical incompatibilities or to provide sequential bioactive release  
 
There are three primary features of coating process: 
• Properties of the substrate 
• Coating process 
• Coating compositions 
 
Several substrate types can be used for coating, ranging from amorphous granules 
to spherical particles (pellets).  Each offer different levels of ease and convenience 
in coating.  One of the most convenient substrates is sugar pellets, which are inert 
spherical particles composed of sucrose and flour, and are used as bioactive 
vehicle for controlled or sustained delivery technologies.  Figure 12 demonstrates 
the mechanism of film coating formation.  
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Figure 12: Schematic of film coating  
(from Glatt, Undated). 
2.8 Phloridizin (PHZ) as a model bioactive 
Phloridizin (Figure 13) is a natural product found in a number of fruit trees.  It 
inhibits sodium-glucose transporters located in the proximal renal tubule and 
mucosa of the small intestine, resulting in increased renal glucose elimination 
(Ehrenkranz et al. 2005). 
 
Figure 13: Chemical structure of phloridizin. 
 
Phloridizin can be analytically detected using HPLC (Escarpa and Gonzalez 1998) 
and by measuring UV absorbance at about 280 nm (Lin et al. 2000).  Molecular 
weight of phloridizin is 436.44 g/mol. The molar extinction coefficient of pure 
phloridizin is approximately 18,000 m2 · mol-1. 
Due to its safety and the ease of measuring a physiological response, phloridizin 
has been used as a research tool for over 150 years.  Apart from use in laboratory 
animals, phloridizin has been also used to explore metabolic adaptations 
associated with irreversible glucose loss in cattle (Meier et al. 2008). 
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Because of its safety (ACVM approval #A009723), pharmacological efficacy, 
good dose-response correlation and ease in measuring physiological response, 
phloridizin was selected as a model bioactive for this project.  It can be readily 
granulated and therefore has sufficient physical stability to be coated with an 
organic coating polymer such as Eudragit® E.  
 
2.9 Summary and objectives 
Coated phloridizin particles, which should withstand ruminal degradation, can be 
suspended in appropriate medium, and delivered from a rumen controlled-release 
device (McLellan 2007). A reliable, reproducible and controllable release of 
rumen protected phloridizin particles is the goal of this project. 
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3.1 Materials 
The following chemicals and materials were used in the study: 
Acetone (BDH Laboratory Supplies, England) 
Citric acid (BDH Laboratory Supplies, England) 
di-Sodium hydrogen orthophosphate 2-hydrate (Na2HPO4 · 2H2O)                    
(VWR International Ltd., England) 
Eudragit® E (Degussa Coatings & Colorants Pty Ltd, Dandenong, Australia) 
Hydrochloric acid (HCl) 36% w/w (Ajax Finechem, Australia) 
Hydroxypropyl methylcellulose (HPMC) (Metolose®, Shin-Etsu, Japan) 
Phloridizin (PHZ) 80% purity (Green Way, China)  
Polyvinylpyrrolidone (PVP) (VWR International Ltd., England) 
Sodium citrate (BDH Laboratory Supplies, England) 
Sodium dihydrogen orthophosphate 1-hydrate (NaH2PO4 · H2O)                    
(VWR International Ltd., England) 
Sugar granules (JK Settler, pure cane white sugar) 
Sugar pellets (Golden Bridge Marketing Ltd, Auckland, New Zealand) 
 
3.2 Equipment 
Spray applicators - Spray application for granulating was achieved using a hand-
held 500-mL spray bottle delivering about 0.7 mL per trigger action.  For coating, 
a touch-up spray gun (T100, Airpower Superworks) connected to an air 
compressor was operated between 2 and 3 atmospheres to deliver a fine mist of 
spraying solution.  
Pan Coater – The pan (Figure 14) was made by joining the rims of two strong 
295-mm diameter plastic bowls (THBN, The Warehouse, Hamilton).  The base of 
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one bowl had been removed (to provide an opening) and a 5-mm diameter bolt 
had been inserted into the base of the other.  The bolt was then attached to a 
Heidolph RZR 1 variable speed motor.  To minimize particles being lost from the 
pan, the opening was covered with cotton fabric with 0.3 mm pores.  The fabric 
had a 5-cm diameter orifice to allow the spray and air streams into the coater.  
 
Figure 14: Coating equipment. 
 
 
 
Figure 15: Spraying with a touch-up spray gun. 
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3.3 General laboratory methods 
When required, samples were air dried in a 60oC oven and cooled to room 
temperature in a dessicator with silica gel.  
 MilliQ water (deionized reverse osmosis purified) was used for making all 
solutions and suspension formulations.  To ensure complete dissolution, solutions 
were vortexed or stirred.  Suspensions of material were clarified either by 
centrifugation or by filtration using 12.5-mm filter papers (Whatman® No. 2) or 
0.45-µm PVDF microfilters (Biolab, Australia). 
The following dissolution media were used: 
Phosphate buffer, pH 6.5: 0.1 M phosphate buffer was made by weighing 
appropriate amounts of sodium dihydrogen orthophosphate 1-hydrate (NaH2PO4 · 
H20) and di-sodium hydrogen orthophosphate 2-hydrate (Na2HPO4 · 2H2O)                    
and making to a standard volume with water.  The stock buffer was then diluted to 
obtain lower molarity phosphate buffers. 
Citrate buffer, pH 3: 0.1 M citrate buffer was made by weighing appropriate 
amounts of citric acid and sodium citrate and making a standard volume with 
water.  The stock buffer was then diluted to obtain lower molarity citrate buffers. 
Hydrochloric acid HCl, pH 3:  0.1 M HCl was prepared by making an appropriate 
volume of 36% (w/w) HCl to a standard volume with water.  The stock solution 
was diluted with water to obtain 10-3 M HCl (pH 3). 
 
3.4 Analytical methods 
Dry matter determinations were made by weighing samples into pre-dried and 
weighed containers, drying in the 60oC oven and cooling as above. 
Sugar concentrations were measured in Brix (1 degree Brix or °Bx corresponds to 
1% (w/w) sugar of total) using a SR 400 refractometer (Bell Technology Ltd., 
Auckland, New Zealand) with auto-calibration mode.  Calibration was checked 
with standard solutions made from commercial sugar.  
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UV-spectral characteristics of PHZ were measured by Libra 12 (Biochrom Ltd., 
Cambridge, England).  The UV absorbance of PHZ at 285 nm was used for 
analysis.  The instrument had to be warmed up for at least a one hour and re-
zeroed regularly to minimize “drift” in either the lamp or sensors.  To obtain the 
calibration curve, a series of standards were made in water, 0.05 M phosphate 
buffer (pH 6.5) or 10 -3M HCl (pH 3) by diluting a stock solution. 
Sugar in blood and urine of cattle was tested using Precision PlusTM (Medisence 
Pty. Ltd., Australia) blood glucose monitor and disposable electrodes 
 
3.5 Solubility, bioactive content and release rate  
Solubility of PHZ powder at saturation concentration was measured by 
sequentially adding known amounts to fixed volumes of medium (water, buffer or 
acid) with stirring until no more material dissolved.  
To measure the dissolved bioactive content, samples were prepared from known 
amounts of medium and raw materials or coated (or uncoated) granules. The 
resulting concentration in solution was measured by Brix or UV. Coated or 
granulated material had been disrupted by grinding.  Care was needed to 
distinguish between undissolved material and the insoluble ground coating, which 
generally would sediment more quickly due to the size and weight of the 
fragments.   
Dissolution rates were measured by adding known weights of material to a given 
weight or volume of medium in a sealed container that was rotated at 
approximately 60 r.p.m. continually on the bottle roller at 40o C.   
Small samples were taken at known times and assayed using the appropriate 
method for the solute being dissolved. 
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3.6 Physical characteristics of particles  
3.6.1 Average particle weight 
Average particle weight was obtained by measuring the total weight for a known 
number (~100) of sugar pellets. 
3.6.2 Average particle size 
The diameters of 50 randomly chosen sugar pellets were measured with callipers 
(Mitutoyo Corp., Japan) and averaged. Measuring average particle sizes of sugar 
granules were obtained by sieving as in section 3.6.3.  
3.6.3 Particle size distribution 
Approximately 100 g of either sugar pellets or granules was shaken using an 
electromagnetic shaker (EMS-8, Mumbai, India) using a nest of sieves ranging 
from 0.25 to 2.00 mm mesh size.  The separated material fractions were expressed 
as a weight percentage of the total sample.  
 
3.7 Coating amount and/or model bioactive content 
3.7.1 Direct method 
The thickness of Eudragit® E coating was measured by comparing the size of 
coated and uncoated sugar pellets. Coating thickness was calculated from the 
equation: 
Coating thickness = 0.5 · (Dc – Du) 
Where Dc and Du represent diameter of coated and uncoated particles respectively. 
 
3.7.2 Theoretical (maximal) value   
The spray-gun bottle containing a known amount of spraying solution was 
weighed before and after each coating cycle.  The amount of Eudragit® E used 
was calculated from the weight loss of the bottle and known concentration of 
Eudragit® E.  This was compared to the weight of substrate used. 
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3.7.3 Assay for model bioactive content  (sugar and PHZ) 
Prior to measuring the content of poorly soluble PHZ, a known amount of either 
raw PHZ or ground PHZ granules was suspended in a known weight of water and 
stirred until dissolution was considered to be complete.  
 An appropriate amount of either ground sugar material or an aqueous suspension 
of PHZ obtained as described above was weighed into a tarred 15-mL centrifuge 
tube.  About 15 mL of water was added and the tube was re-weighed.  The tube 
was vortexed for 5 min and then centrifuged at 10 000 G for 5 min.  The solution 
was assayed by Brix or UV.  The amount of Eudragit® E was calculated as the 
difference between the total weight of particles and analyzed bioactive content.   
 
3.8 Manufacturing and processing trials 
3.8.1 Granulating PHZ  
The process was a simplified version of the industrial process. 
A 2% w/w aqueous solution of PVP was sprayed at about 1 trigger action per 
second onto a known amount of PHZ spread on a 38 x 25 x 3 cm plastic flat tray 
placed at a 30o angle to the horizontal.  After 20 trigger action, the particles were 
mixed and left to dry for 15 min before repeating the process.  After the final 
spraying phase, the tray was placed into the 60oC oven and dried for 12 h (to 
constant weight). 
Monitoring the amount of binder 
The difference in weight of original tray with sample and dried weight after 
spraying indicated the amount of binder added  
The amount of binder was also estimated by weighing the spray container (and 
contents) after each spraying phase to measure the amount of solution that had 
been applied. 
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3.8.2 Developing a coating procedure 
The standard procedure used a stock solution of 6% w/w Eudragit® E in acetone.  
The pan was 25o to the horizontal axis.  The procedure involved coating about 150 
g of pellets (diameter 1.4-1.7 mm) at a spraying rate of about 3.5 g/min (4.4 
mL/min), with the pan turning at 80 r.p.m.  The spray gun nozzle was set to give 
the narrowest and strongest spray stream possible, and operated at about 10 trigger 
action per min (1 trigger action per 8 pan rotations).  The distance between the 
spray gun nozzle and the bottom of the pan averaged 21 cm.  The dryer was 
placed behind the spray gun and at setting 2 (maximum speed) to give a stream of 
warm air at a 10o angle from the spray gun stream. 
The coating process was continuous except when taking measurements or 
overnight.  After coating was completed, pellets were dried with the fan in a static 
pan for about 30 min to remove any acetone.  
3.8.3 Initial coating study – comparisons of core particles 
To investigate the effect of particle size and shape, and the degree of abrasion 
during the coating process, initial coating trials using sugar pellets and sugar 
granules were performed.  The sugar pellets contain about 15% flour (a binder to 
increase particle robustness).  Their spherical shape minimizes contact between 
particles, reducing agglomeration during the coating process.  The sugar pellets 
were sieved to obtain the 1.7-2.0 mm diameter fraction. The sugar granules were 
sieved to obtain the 0.71-1.00 mm diameter fraction to simulate PHZ granules.   
To assess the extent of abrasion, approximately 160 g of sugar pellets were coated 
with total of about 50 g of Eudragit® E. Small samples of coated sugar pellets 
were taken progressively and the average particle weight was determined. 
Batches of material were made with varying amounts of Eudragit® E.  The 
amount of coating on material was determined (section 3.7.3 above) and the 
dissolution rate of coated material was measured in various media (section 3.5). 
3.8.4 Coated PHZ for in vitro trials 
Three batches of PHZ granules containing 2.7, 1.3 and 0.7% (w/w) PVP 
respectively were separately granulated and coated.  The dissolution rates of 
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coated and uncoated PHZ granules and PHZ powder were measured in pH 6.5, 
0.05 M phosphate buffer and HCl 10-3 M.   
 
3.9 Animal trials  
In a related project, a small series of animal trials was conducted by staff at 
Dexcel Limited using material prepared during this study.  This work is included 
in this thesis because the data are of direct relevance to assessing the coating 
technology and to the overall project that the research in this thesis contributes to.  
Individual credit for data in this section is not claimed by the candidate.  
3.9.1 Animal ethics 
Animal trials were approved independently by the AgResearch Ruakura Animal 
Ethics Committee.  The use of PHZ was approved by Agricultural Compounds 
and Veterinary Medicines group (ACVM approval #A009723, Expiring 1 June 
2009).  Eudragit® E 100 / E PO (an excipient in human pharmaceuticals) and guar 
gum (GRAS Register, CAS No 9000-30-0) were approved ingredients. 
3.9.2 Unprotected PHZ  
The objective of these studies was to assess effectiveness of the physiological 
response of unprotected (i.e. uncoated) PHZ.  Single doses of unprotected PHZ 
powder  were administered as a suspension in 60 mL water, with 0.5 - 1.0 g guar 
gum to aid in suspension, directly into the abomasum of fistulated cows (Table 2) 
via a 1.2-m flexible PVC tube with a 200-mm, 10-mm internal diameter stainless 
steel tube on one end.  
Table 2: Animal studies with unprotected PHZ. 
  
 Trial 1 Trial 2 
Number of animals 2 5 
PHZ single dose (g) 4 or 8 0, 2, 4, 8, 16 
 
 
Samples of urine were collected at known time intervals and screened for glucose 
(section 3.4). 
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3.9.3 Protected PHZ  
The objective was to compare the physiological effectiveness of protected and 
unprotected PHZ when administered into the abomasum.  The trial involved 
administration of PHZ directly to the abomasum of fistulated cows with a 16 g 
single dose of unprotected and protected PHZ. Process was repeated 2 days later 
with treatments being over-crossed. 
The product was suspended in water (day 1) or in 5% w/w HPMC in water gel 
(day 2).  Samples of urine were collected at 2-h intervals for up to 12 h and 
screened for glucose (section 3.4). 
 
3.10 Active Rumen Technology (ART) 
The concept of Active Rumen Technology, which involves intraruminal bioactive 
delivery using elevated gas pressure, is described in section 2.4.4. 
This section describes controlled in vitro delivery of protected PHZ.  To explore 
the relation between in vitro release rate and the payload of coated bioactive a 
series of devices were made up of aqueous 6% w/w HPMC gel with 0%, 5%, 10% 
and 15% (w/w) of coated PHZ. For each concentration, five devices were 
assembled. 
3.10.1 Preparing the bioactive formulation 
HPMC gel was centrifuged in 50-mL tubes for 5 min at 5000 G to remove air. 
Known amounts of coated protected PHZ particles were carefully mixed into in 
the gel to obtain the required content by weight. Devices were carefully filled with 
the formulation so no aeration resulted.  
3.10.2 Manufacturing the devices  
Syringe barrels with low gas permeability and low friction plungers were used. 
The barrel orifice of each was extended to 6 mm diameter.  
 
The following components (Figure 16) for manufacturing the devices were used: 
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• 7-mL BD Epilor® barrels and plungers  
• hydrogen producing gas cell (Varta 4690 11.6-mm by 5.4-mm gas-producing 
cell, Simatec, Switzerland) 
• resistors 1800 Ω  
• sealing components: rubber plugs, plastic holding plates 
 
 
Figure 16: Components of the ART device. 
 
After carefully filling with formulation (Figure 17), the plunger was placed into 
the barrel followed by a gas cell. Each device was sealed by attaching a holding 
plate to the base of the barrel.  
 
Figure 17: ART devices filled with bioactive formulation. 
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3.10.3 Measuring release rate  
All devices were placed horizontally on the test tube rack and pre-weighed 5-mL 
sample tubes were placed under the orifices of the barrels to collect expelled 
material.  At regular times, devices were weighed and the plunger position 
measured on two opposite sides using callipers. To measure the amount of solid 
material released, the test tubes with collected material were dried and weighed.  
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4.1  Granulating PHZ 
4.1.1 Analysis of PHZ powder 
 UV absorbance 
The UV spectra of PHZ in the different media at concentrations of about 30 
µg/mL showed that the spectra are essentially independent of medium and/or pH 
in the spectral region of analytical interest (Figure 18). Routine analysis used the 
maximum absorbance at 285 nm. 
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Figure 18: UV spectra in different media. 
  
 
Beer’s law plots in all media were linear, yielding a common slope (Figure 19). 
This was use in all subsequent assays.  
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Figure 19: UV absorbance of PHZ in different media. 
 
The molar extinction coefficient for powdered PHZ was calculated using the mean 
regression line (Figure 19) and is of the order of 12,600 m2 · mol-1. Considering 
the PHZ used was only 80% pure (section 3.1), the calculated value (15,800 m2 · 
mol-1) is within about 15% of the literature value of about 18,000 m2 · mol-1. 
Solubility determination 
Duplicated assays demonstrated that solubility of PHZ was dependent on pH, but 
apparently also affected by the ionic nature of the medium (Table 3). 
 
 Table 3: Solubility of PHZ powder. 
 
Medium Solubility (g/L) 
 
Water 
 
1.15 
 
Phosphate buffer pH 6.5, 0.05M 
 
1.94 
 
HCl pH 3 
 
0.91 
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4.1.2 The effect of PVP  
PVP was used as a binding material for granulating PHZ. Three batches of 0.71 -
1.00 mm diameter PVP granules with 2.7, 1.3 and 0.7% (w/w) PVP content 
respectively were manufactured. 
The dissolution of granules in phosphate buffer showed that PVP had only a small 
effect on initial dissolution rate (Figure 20).  All granules reached 85-95% 
dissolution after 180 min.  
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Figure 20: Dissolution profiles of uncoated PHZ granules containing 
different amounts of PVP (% w/w) in pH 6.5, 0.05 M phosphate buffer. 
 
 
4.2 Developing a coating procedure – practical 
observations 
 
Preliminary studies used sugar pellets to explore the effect of varying different 
parameters, and to gain experience in using the equipment. 
Rotation speed 
Industry tends to use for coating tablets rotation speeds of the order of less than 15 
r.p.m. (Lachman et al. 1986).  This rotation speed appeared to be too low for 
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small (2 mm) particles as they tend to agglomerate.  If pan rotation speed 
exceeded 90 r.p.m, the particles were centrifugally forced out and glued to the pan 
coater walls.  The optimal rotation speed for 150 g of 1.4 - 1.7 mm diameter sugar 
pellets was 80 r.p.m. 
Angular position  
The optimum angular position, when coating about 150 g of 1.4 - 1.7 mm 
diameter sugar pellets was on average 30º.  
Composition of the spray solution 
The initial composition of the spray solution was adapted from the Degussa 
Eudragit® E specification sheets (Degussa, Undated).  However it was found that 
the coated material dried too slowly, causing increased gluing of the material.  
This appeared to be due to the water and isopropyl alcohol content so they were 
therefore omitted from the spray.  
Talc is normally added as a glidant to prevent gluing of the particles.  However, 
exploratory trials showed that talc did not increase the coating efficiency but 
could interfere with analytical methods because it was incorporated in the coating.  
Therefore, talc was excluded from the spray solution. 
The composition of spraying solution adopted for routine studies was 6% (w/w) 
Eudragit® E in acetone.  
Spraying rate 
A spraying rate of 1 trigger action per 8 pan rotations was found to be the most 
efficient in terms of drying rate.  The weight of spraying solution expelled 
depends on the spray gun settings but on average corresponded to about 3.5 g of 
spraying solution per minute.  
Spray gun settings 
The spray gun was set to produce a spray that would reach the epicentre of the pan 
coater but not to the pan wall behind the epicentre.  
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Pan rotation time 
When the particles rotated in the pan, they were exposed to high mechanical 
forces between the particles and also between themselves and the pan walls.  This 
facilitated abrasion (section 3.8.3) of particle surface resulting in decreased 
particle weight and size, which is demonstrated in the Figure 21. There was a 
small weight loss at the start of the process (i.e. when there was only a small 
amount of added Eudragit® E), but this stopped after 15 g of Eudragit® E had 
been added and average particle weight increased. 
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Figure 21: Effect of processing time (expressed as added Eudragit® E) on 
average particle weight. 
 
4.3 Coating using different model substrates 
4.3.1 Sugar pellets 
Coating efficiency  
To estimate the efficiency of the coating process and degree of protection in vitro, 
two batches of coated sugar pellets with varying amounts of Eudragit® E. were 
produced.  Particle weight, thickness and % coating of each batch were 
determined (Table 4). 
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Table 4: Eudragit® E coating content of sugar pellets 
(UP - uncoated sugar pellets; CP 2 – medium coating; CP 3 – extended coating). 
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UP 0.0 0.0 0.0 1.52 0.0 0 3.09 0.0 100.0 0.0 
CP2 661 39.6 20.9 1.63 0.11 55 3.58 13.6 86.7 13.3 
CP3 1557 93.4 38.4 1.81 0.29 145 4.35 29.8 73.5 26.5 
 
The coating of CP3 was about twice that on CP2, whether measured by theoretical 
amount of Eudragit® E added, diameter of particles or increase in weight.  
Comparison of the theoretical values to those calculated by measuring Brix, 
deliver coating efficiency values of about 65%. 
In vitro dissolution rates 
Eudragit®E coated sugar pellets dissolve only slowly in water (Figure 22).  It 
took about 24 hours for 10% of the sugar to be solubilised from CP2 and much 
longer for the more heavily coated CP3.  
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Figure 22: Effect of Eudragit® E coating content on dissolution of coated 
sugar pellets in water. 
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Figure 23: Effect of Eudragit® E coating content on dissolution of coated 
sugar pellets in pH 6.5, 0.05 M phosphate buffer. 
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Assuming that phosphate buffer is representative of rumen fluid, 90% protection 
would be afforded for up to about 9 hours (about 540 min) for extended coating 
(28.9% Eudragit® E) and only 2 hours (about 120 min) for medium coating 
(13.6% Eudragit® E). 
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Figure 24: Effect of Eudragit® E coating content on dissolution of coated 
sugar pellets in pH 3, 0.05 M citrate buffer.  
 
The time to release 50% of sugar from coated sugar pellets for both 13.6 and 
28.9% E coating (CP2 and CP3) in the pH 3, 0.05 M citrate buffer is on average 
80 times shorter than in phosphate buffer and on average 350 times shorter than 
when in water (Figure 24).  
Molarity of the medium 
Because the particles dissolved more rapidly in neutral phosphate buffer than in 
water at a similar pH, it was thought that the presence of ions (ionic strength) also 
influenced disintegration of the coating.  This was investigated by comparing 
dissolution rates of coated material in pH 3 citrate buffers of different molarities 
(Figure 25).   
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Figure 25: Effect of citrate buffer molarity on dissolution of coated sugar 
pellets 
a) 13.6% Eudragit® E coating (CP2) 
b) 28.9% Eudragit® E coating (CP3). 
 
While not as extensive as the effect of water and phosphate buffer, both different 
coating degrees of particles (i.e. different coating levels) did dissolve more 
quickly at the higher molarity. 
4.3.2  Sugar granules 
Coating efficiency  
To estimate the efficiency of the coating process and degree of protection in vitro, 
three batches of coated 0.50 – 0.71 mm sugar granules with varying amounts of 
Eudragit® E were produced.  Percentage of Eudragit® E coating of each batch 
was determined.  
Table 5: Eudragit® E content of 0.50-0.71 mm sugar granules 
(UG - uncoated sugar granules, CG 1 – light coating, CG 2 – medium coating, CG 3 - 
extended coating) 
Calculated by measuring  Brix Product Theoretical (max.) 
value (% w/w) Sugar % (w/w) Eudragit® E 
% (w/w) 
UG 0.0 100.0 0.0 
CG1 5.9 97.0 3.0 
CG2 19.9 88.4 11.6 
CG3 40.0 75.2 24.8 
 
Comparison of the values for applied (theoretical) and calculated by measuring 
Brix percentage of Eudragit® E coating (Table 5) indicates that coating efficiency 
of 0.50-0.71 mm  sugar granules was of the order of 60%. 
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In vitro dissolution rates 
Similarly to the dissolution rates of sugar pellets, sugar granules with more 
Eudragit® E coating dissolve slower than those with less Eudragit® E coating 
(Figure 26).  Particles with a very thin coating (3% coating) were 90% dissolved 
within 60 min but those with the thickest coating (27.4% coating) were only 10% 
dissolved after 180 min.  
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Figure 26: Effect of Eudragit® E coating content on dissolution of coated 
sugar granules in water. 
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Figure 27: Effect of Eudragit® E coating content on dissolution of coated 
sugar granules in pH 6.5, 0.05 M phosphate buffer. 
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Coating thickness also affected dissolution in pH 6.5, 0.05 M phosphate buffer 
(Figure 27). However, particles of similar coating thickness dissolved more 
quickly in phosphate buffer than in water.  For example, particles with 24.8% 
coating were 50% dissolved after 120 min compared with only 5% when in water.   
All particles were completely dissolved within 16 minutes when immersed in pH 
3, 0.05 M citrate buffer (Appendix A.6.3). 
 
4.4 Coating PHZ granules 
Coating efficiency  
To estimate the likely coating efficiency, three different (25g) batches (2.7, 1.3 
and 0.7% (w/w) PVP respectively) of 0.71 – 1.00 mm PHZ granules were coated 
in a normal fashion except for small samples were taken progressively during this 
process for quantitative analysis and calculating coating efficiency. 
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Figure 28: Correlation between measured and applied Eudragit® E of three 
batches (B1, B2, B3) of 0.71 – 1.00 mm PHZ granules. 
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The data indicated little difference between the batches (Figure 28).  The coating 
efficiency is only about of the order of 50%, which was lower than either granules 
(60%) or pellets (65%).  These differences are possibly due to particle properties 
such as size, shape, abrasion and tendency to stick together and fragment. 
 
In vitro dissolution rates 
The dissolution rate profiles of coated PHZ granules of two different particle sizes 
were measured. 
The dissolution rate profiles of small (0.50-0.71 mm) 21.5% Eudragit® E coated 
PHZ granules in different media were compared (Figure 29). Because the smaller 
PHZ granules were subject to static electricity they readily became attached to the 
walls of the pan coater walls, which complicated the coating process. 
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Figure 29: pH dependent release of PHZ from small (0.71-1.00 mm) 21.5%  
Eudragit® E coated PHZ granules.  
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Dissolution rates of two batches of larger (0.71-1.00 mm) PHZ granules varying in 
Eudragit® E amount and raw PHZ were measure in phosphate buffer (Figure 30). 
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Figure 30: Effect of Eudragit® E coating content on PHZ release from 0.71 - 
1.00 mm coated PHZ granules in pH 6.5, 0.05 M phosphate buffer. 
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Figure 31: Effect of Eudragit® E coating content on PHZ release from 0.71 - 
1.00 mm PHZ granules in pH 3 HCl.  
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Once again it is seen that the higher the level of coating, the slower the dissolution 
rate of the coated material and dissolution rate in pH 3 is faster than in pH 6.5 
(Figures 30 and 31). 
The profiles obtained showed a similar trend with the previous studies using sugar 
pellets and granules. However, the presence of PVP in the PHZ granules 
apparently contributes to generally slower dissolution rates than those of sugar 
products. 
 
4.5 PHZ granules for in vivo trials 
Coating efficiency  
A new 170-g batch of 0.71-1.00 mm coated PHZ granules was manufactured by 
using a standard coating procedure except for intervals at which the spraying was 
interrupted in order to weigh the coated material.  
The total amount of Eudragit® E sprayed was plotted with increase in weight of 
coated product (Figure 32).  The amount of particles that were lost from the pan 
coater was considered in the calculation. 
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Figure 32: Effect of total Eudragit® E applied on increase in total weight of 
coated product. 
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Using this approach coating efficiency is about 70%. This is higher than the 
previous observation with smaller batches of PHZ granules (section Coating 
efficiency in 4.4) 
Accurate measure of Eudragit® E coating 
The final product was assayed by UV absorbance and the amount of Eudragit® E 
coating was calculated as the difference between the amount of PHZ in coated and 
uncoated particles (Table 6). 
Table 6: Amount of Eudragit® E applied to the PHZ powder. 
 
Product n % (w/w) PHZ 
St. 
dev. 
% 
Eudragit® E 
Uncoated granules 4 96.0 0.8 0 
Coated granules 4 73.2 1.8 22.8 
 
In vitro dissolution rates 
The pH of the environment affected the dissolution of coated PHZ that were to be 
used in the in vivo trials (Figure 33), showing that PHZ release through the 
Eudragit® E coating was pH dependant. 
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Figure 33: Effect of pH on PHZ release (pH 3 HCl vs. pH 6.5, 0.05 M 
phosphate buffer). 
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4.6 Animal trials   
The trials using PHZ as a model bioactive were only partly successful. In the first 
instance, (Trial 1) doses of 8 and 16 g PHZ elicited responses in urinary sugar 
levels, while low doses were not detected.  There was no demonstrated effect on 
blood sugar levels. 
In the second trial using five cows in a Latin square design, there was a relatively 
consistent response from the 8 and 16 g doses, but not from the lower dose levels. 
The results of the final trial (Trial 3) comparing coated and uncoated material was 
less convincing.  Of the six cows used, three gave urinary sugar responses to 
coated PHZ, while only one responded to uncoated material.  
The final reports on these trials indicate concern about the adequacy of the intra-
abomasal infusion technique.  It appears probable that much of the dose is not 
introduced either adequately, or sufficiently deeply, into the omasum for it to be 
carried automatically into the abomasum, and so much of it may “reflux” back 
into the rumen. 
None-the-less, the data indicate that PHZ can elicit an easily measured response 
from the host animal, and it could therefore be a suitable model compound for 
further studies of granulated and coated bioactive. 
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4.7 Active Rumen Technology (ART) 
Release rates of bioactive formulation from ART devices are presented in Figure 
34. 
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Figure 34: Release of the formulation from the ART devices  
(devices 1-5: 15 % bioactive, 6-10: 10 % bioactive, 11-15: 5 % bioactive, 16-20: no 
bioactive). 
 
The curvature of the profiles was thought to be due to the outward gas diffusion 
through the device barrel walls (McLellan 2007). It is shown that contents release 
from devices with the high bioactive payload (devices 1-10) slowed down sooner 
than those with no bioactive (devices 16-20) or low payload (devices 11-15). 
However, this slow down is observed in the final stage of the release, suggesting 
that generally the content of bioactive in form of granules does not considerably 
affect the releasing performance of the ART device.  Due to the physical 
properties of the formulation based on HPMC gel, PHZ granules tended to stick 
together and clog at the device orifice as the gel formulation was drying out.  
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Figure 35: Release of solid material consisting of PHZ granules and HPMC 
(devices 1-5: 15 % bioactive, 6-10: 10 % bioactive, 11-15: 5 % bioactive, 16-20: no 
bioactive). 
 
The previous results (Figure 34) are consistent with those presented in Figure 35. 
However, in this case the difference between four populations of used ART 
devices is more obvious, and the terminal amounts of solid material released is 
consistent with the content of PHZ granules in the formulation.  
The release profiles from Figure 37 demonstrate that sustained and controlled in 
vitro bioactive release using Active Rumen Technology is in principle feasible. 
However, further research has to be done. 
 The release rate can be modified by applying different resistors and the linearity 
of the profiles can be achieved by using an appropriate barrel wall material.  
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5.1 Conclusions 
Pan coating process 
The pan coating method used in this study requires considerable optimization of 
the material to be coated, and of the equipment. The efficiency of the method 
depends on following parameters: 
• Material characteristics 
Particle size and shape – Generally, smaller rectangular particles (sugar granules) 
tended to more agglomeration and adhering to the pan coater walls, resulting in 
extensive gluing together of particles.   
Starting weight of material - The efficiency of applied pan coating procedure 
decreases with lower amounts of starting material.  
• Process parameters 
Composition of spray solution - The most efficient spray composition was shown 
to be 6% w/w of coating material (Eudragit® E) in acetone. Inclusion of water, 
talc (glidant) and/or isopropylalcohol did not contribute to better coating and, on 
the contrary, slowed down the process and led to more particle adhering together. 
In addition, talc tended to become incorporated in the coating and interfered with 
analytical methods. 
Pan rotation speed - Coating at pan rotation speed of about 80 r.p.m. provided 
better fluidizing of particles and resulted in better efficiency and quality of 
coating. 
Spraying rate - Spraying rates of about 3.5 g/min showed to be the most suitable 
in terms of optimal ratio of drying and rotation time.  
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Dissolution/disintegration of Eudragit® E coated material 
Measuring in vitro dissolution rate by rotating the material in a vial is a quick and 
convenient method and can be applied as an alternative to standard dissolution 
rate methods specified by USP (The United States Pharmacopoeia). 
Each type of coated substrates that have been used has shown a delay in 
dissolution rates in comparison to uncoated material, and a pH-dependent release 
profile.  
In vitro dissolution profiles of both sugar pellets and granules suggest that the 
amount of Eudragit® E coating is not directly proportional to dissolution time of 
material. 
Bioactive release through Eudragit® E coating depends on following factors: 
• pH of medium 
• molarity of medium  
 
Bioactive controlled delivery using ART 
In this study it was shown that in principle the controlled and reproducible 
delivery of a particulate, rumen-protected bioactive from a gas pressure driven 
rumen device is possible.  
The release profiles of a larger number of devices (n=20) were reproducible and 
generally independent of the bioactive content over several days, confirming that 
the coating and release technologies are compatible.  However, a limitation in 
bioactive payload was observed: the ART devices loaded with 15% bioactive 
payload released only about 80% of the content, which was thought to be due to 
drying out of HPMC gel. 
Controlled and linear bioactive delivery over longer period of time could be 
expected to result from optimizing the bioactive formulation and the parameters of 
the ART device.   
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5.2 Recommendations 
In this section recommendations for a generic rumen controlled delivery system 
with a protected bioactive are given.  
Rumen protection 
Ideally, spherical bioactive particles will be either microencapsulated or coated 
using fluidized bed coating.  Microencapsulation is a preferential option as it will 
yield much smaller protected bioactive particles, which could be better suspended 
and homogenized in a formulation, and easier released through an ideally very 
small orifice of the ART device.  
The protective coating could be a combination of different coating materials to 
delay microbial digestion. To augment the efficiency of rumen protection, traces 
of an appropriate and safe antibiotic agent could be added into the coating. 
 Formulation 
The formulation will be preferentially an inorganic matrix (e.g. bentonite gels) to 
prevent its degradation by ruminal bacteria, which are capable of migrating into 
the device and digesting the bioactive formulation. The addition of small amounts 
of a safe antibiotic agent into the formulation will minimize the chance of 
bacterial colonization.  Appropriate viscosity and consistency of the matrix will 
ensure more uniform and long-term suspension of bioactive particles.  
Rumen controlled release device 
To ensure the linearity of the bioactive release, the barrel of the device will be 
manufactured from material that ideally is impermeable to hydrogen and ruminal 
gases.  A low friction plunger could be designed to have multiple points of contact 
with barrel walls to minimize chances of gas or formulation passing between the 
plunger and the barrel walls. 
Future vision 
Controlled intraruminal release of an effectively protected bioactive would reveal 
new opportunities for administration of a wide range of bioactives which, when 
unprotected, are unstable in the rumen. This might result in new approaches for 
improving health care and the productivity of livestock.  
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A.1 Calibrating UV spectrophotometer 
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A.2 Calibrating Brix device 
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A.4 The effect of PVP  
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116 B1 159.57 264.721 105.151 76.8 0.547 14.233 0.665 17.291 604.210 729.845 82.8
B2 159.305 266.522 107.217 80.1 0.558 13.995 1.013 25.393 887.512 746.525
B3 159.093 267.495 108.402 81.3 0.575 14.290 0.879 21.845 763.457 749.424
176 B1 159.57 264.721 105.151 76.8 0.686 14.487 0.894 18.880 659.768 729.845 90.4
B2 159.305 266.522 107.217 80.1 0.452 15.064 0.621 20.696 723.291 746.525 96.9
B3 159.093 267.495 108.402 81.3 0.629 14.399 0.898 20.557 718.417 749.424 95.9
311 B1 159.57 264.721 105.151 76.8 0.709 15.415 0.894 19.437 679.267 729.845 93.1
B2 159.305 266.522 107.217 80.1 0.551 15.585 0.731 20.676 722.591 746.525 96.8
B3 159.093 267.495 108.402 81.3 0.643 14.255 0.926 20.529 717.440 749.424
1020 B1 159.57 264.721 105.151 76.8 0.445 10.117 0.874 19.870 694.407 729.845 95.1
B2 159.305 266.522 107.217 80.1 0.437 9.984 0.880 20.105 702.618 746.525 94.1
B3 159.093 267.495 108.402 81.3 0.295 10.397 0.580 20.442 714.383 749.424 95.3
2940 B1 159.57 264.721 105.151 76.8 0.442 10.075 0.852 19.412 678.398 729.845 93.0
B2 159.305 266.522 107.217 80.1 0.578 9.598 1.235 20.496 716.291 746.525 96.0
B3 159.093 267.495 108.402 81.3 0.278 10.056 0.571 20.661 722.070 749.424 96.4
 
 
 
 
A.5 Sugar pellets 
A.5.1 Effect of processing time 
Intermidiate product
Sugar Pellets P0 P10 P15 P2 P3 P4 P5 P6
weight pellets
beforecoating [g] 156.00 126.00 127.23 121.00 125.70 127.39 126.00 128.63
m Eudragit [g] total 0.00 0.80 15.40 24.07 28.10 33.11 38.08 43.08 50.49
m Eudragit [g]/100g
pellets
0.00 0.51 12.22 6.81 3.33 3.99 3.90 3.97 5.76
m Eudragit [g]/100g
cummulative
0.00 0.51 12.73 19.55 22.88 26.86 30.76 34.73 40.49
average particle size
[mm] 1.59 1.63 1.61 1.61 1.66 1.66
average particle
weight [mg] 3.09 3.01 3.02 3.06 3.15 3.23 3.33 3.40 3.55
diff. from initial
particle mass in %
0.00 -0.03 -0.02 -0.01 0.02 0.04 0.07 0.09 0.13
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A.5.2 Eudragit® E content - theoretical (max.) value 
A.5.2.1 Coating CP2 (medium coating) 
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%
 
[w
/w
]
150 62.3 3.738 18 3.46
100 6 3.212 3.71
72.1 4.326 19 3.79 3.178 2.68
117.4 7.044 31 3.79
98.7 5.922 23 4.29 3.36 7.95
110.5 6.63 25 4.42
99.6 5.976 26 3.83 3.7 16.41
total [g] 660.6 39.636
 
 
A.5.2.2 Coating CP3 (extended coating) 
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%
 
[w
/w
]
150 117 7.02 29
118 7.08 30
134.7 8.082 31
126.4 7.584
121 7.26 3.5789 13.58
44 2.64 11 4
130.7 7.842
73.2 4.392
121.6 7.296 29.9 4.07
116.3 6.978 25.5 4.56
79.2 4.752
87 5.22 4.061 23.84
99 5.94
40 2.4 4.04 23.44
73 4.38 4.179 25.99
76 4.56 4.3543 28.97
total [g] 1557.1 93.426
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A.5.3 Average particle size  
UP (uncoated sugar pellets) (n=50) 
1.67 1.7 1.68 1.7 1.56
1.64 1.53 1.58 1.56 1.65
1.51 1.51 1.45 1.54 1.79
1.7 1.55 1.49 1.68 1.64
1.72 1.66 1.55 1.69 1.62
1.47 1.64 1.4 1.57 1.56
1.57 1.51 1.58 1.65 1.39
1.6 1.58 1.65 1.65 1.62
1.6 1.53 1.62 1.77 1.58
1.5 1.55 1.58 1.52 1.63
 
CP2 (sugar pellets with medium coating) (n=50) 
1.58 1.57 1.71 1.55 1.60
1.59 1.72 1.46 1.68 1.60
1.68 1.67 1.76 1.65 1.61
1.58 1.68 1.62 1.58 1.70
1.57 1.57 1.63 1.63 1.58
1.70 1.73 1.48 1.64 1.65
1.62 1.67 1.64 1.68 1.59
1.53 1.57 1.64 1.69 1.65
1.71 1.67 1.55 1.56 1.74
1.68 1.67 1.68 1.60 1.59
 
CP3 (sugar pellets with extended coating) (n=50) 
1.82 1.88 1.74 1.94 1.80
1.88 1.86 1.66 1.88 1.92
1.87 1.79 1.75 1.89 1.82
1.73 1.72 1.78 1.80 1.83
1.80 1.77 1.82 1.90 1.89
1.83 1.78 1.71 1.67 1.69
1.75 1.81 1.87 1.80 1.86
1.65 1.70 1.97 1.94 1.81
1.72 1.88 1.83 1.84 1.80
1.71 1.84 1.78 1.91 1.77
 
A.5.3.1 Particle weight 
  
number 
of 
particles 
total 
sample 
weight [g] 
average 
particle weight 
[mg] 
coating 
% 
[w/w] 
Uncoated sugar pellets 100 0.309 3.093 0.0 
Coated 13.6 % sugar 
pellets 100 0.358 3.58 13.6 
Coated 28.9 % sugar 
pellets 100 0.435 4.354 28.9 
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A.5.4 Eudragit® E content - measuring Brix 
weight 
material [g]
weight sugar 
in material [g] weight total [g]
sugar % 
[w/w] theor. brix
sugar % [w/w] 
brix measured
Eudragit coating 
% [w/w]
Uncoated pellets (UP)
0 0 0.000 10.212 0.00 0.0 0.0
1 0.561 0.482 10.185 4.73 4.8 100.6
2 1.125 0.967 10.643 9.08 8.9 98.5
3 1.751 1.504 11.307 13.31 13.3 99.8
4 2.299 1.975 11.286 17.50 17.7 101.1
av. 100.0 0.00
13.6% pellets (CP2)
0 0 0.000 9.876 0.00 0.0 0.0
1 0.545 0.468 10.134 4.62 4.1 88.0
2 1.122 0.964 9.283 10.38 8.7 84.2
3 1.773 1.523 9.833 15.49 13.5 87.3
4 2.383 2.047 9.783 20.93 18.3 87.4
av. 86.7 13.27
28.9% pellets (CP3)
0 0 0.000 10.231 0.00 0.0 0.0
1 0.554 0.476 9.687 4.91 3.5 70.6
2 1.163 0.999 10.746 9.30 6.7 72.1
3 1.76 1.512 9.388 16.11 12.1 75.3
4 2.368 2.035 9.857 20.64 15.7 75.9
av. 73.5 26.54
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A.5.5 In vitro dissolution rates 
MilliQ water Phosphate buffer Citrate buffer
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time 
[min] brix
% of
max brix
% of
max brix
% of
max brix
% of
max brix
% of
max brix
% of
max
time 
[min]
0 0.0 0.0 0.0 0.0 0.7 0.0 0.7 0.0 1.0 0.0 1.0 0.0 0
1 1
2 0.7 0.0 0.7 0.0 2.0 12.8 2.6 20.5 2
6 0.0 0.0 0.0 0.0 6
7 0.8 0.8 0.8 0.7 4.6 46.2 8.6 97.4 7
12 6.8 74.4 8.7 98.7 12
16 7.9 88.5 16
17 0.8 0.8 0.8 0.7 17
18 0.0 0.0 0.0 0.0 18
20 8.8 100.0 20
23 8.8 100.0 23
25 8.8 100.0 25
26 26
27 0.8 0.8 0.8 1.4 27
42 0.8 1.6 0.8 1.4 42
43 43
45 0.0 0.0 0.0 0.0 45
57 0.9 2.5 0.8 1.4 57
71 0.0 0.0 0.1 0.7 71
82 0.8 1.6 0.9 2.8 82
102 0.9 3.3 1.0 4.2 102
126 0.0 0.0 0.2 3.0 126
135 1.0 4.9 1.2 7.0 135
175 1.0 4.9 1.8 14.7 175
210 0.0 0.0 0.2 3.0 210
217 217
220 1.1 5.7 3.2 35.0 220
258 1.0 4.1 5.0 60.1 258
353 0.0 0.0 0.2 2.2 353
360 1.0 4.9 7.2 90.9 360
458 0.0 0.0 0.3 4.5 458
468 1.2 7.4 7.4 93.0 468
1187 0.1 1.8 0.7 9.7 1187
1192 5.4 77.0 7.8 98.6 1192
1260 0.2 3.6 0.9 13.4 1260
1470 0.2 3.6 1.3 19.4 6.4 92.6 7.9 100.0 1470
1980 0.4 6.4 2.4 35.8 6.9 100.8 7.9 100.7 1980
2580 0.5 9.1 3.6 53.7 6.8 100.0 7.8 99.3 2580
3520 0.7 12.7 5.3 78.2 6.7 98.4 3520
3940 0.8 14.5 5.6 83.5 3940
7720 1.9 34.5 6.5 96.9 7720
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A.5.6 Effect of molarity  
CP 3 CP 2 CP 3 CP 2 CP 3 CP 2
0.05M 0.05M 0.1M 0.1M 0.2M 0.2M
time [min] brix % of max brix % of max brix % of max brix % of max brix % of max brix % of max
0 1.1 0.0 1.1 0.0 2.0 0.0 2.0 0.0 3.8 0.0 3.8 0.0
1
2 2.2 23.4 3.0 37.0 3.3 35.1 4.0 46.0 5.1 47.2 6.1 57.0
3
4
5
6 3.9 41.5 7.9 97.5 6.3 67.0 8.0 92.0 8.6 79.6 10.5 98.1
7
8
9
10 6.9 73.4 8.1 100.0 8.5 90.4 8.7 100.0 10.8 100.0 10.8 100.9
11
12
13
14 9.0 95.7 8.1 100.0 9.1 96.8 8.7 100.0 10.9 100.5
15 10.7 100.0
16
17
18 9.4 100.0 9.5 101.1 10.8 100.0
19 8.7 100.0
20
21
22 9.4 100.0 9.4 100.0
 
A.6  Sugar granules 
A.6.1 Eudragit® E content - theoretical (max) value 
Pr
od
u
ct
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%
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/w
]
CG1 103.0 38 2.3 2.2 5.88
CG2 65 151 9.1 13.9 19.90
CG3 18 89.7 5.4 29.9 39.98
 
A.6.2 Eudragit® E content - measuring Brix 
p
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sa
m
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d
 
p
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 +
 
w
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r 
[g
]
S
u
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%
 
(w
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) 
o
f 
to
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B
ri
x
 
m
e
a
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re
d
 E
u
d
ra
g
it
 
co
a
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n
g
 %
 
w
/w
CG1 1 4.2657 9.7 9.4 2.8
2 4.3757 9.2 8.9 3.1
av. = 3.0
CG2 1 8.8988 10.2 9.0 11.2
2 8.8358 9.8 8.6 12.1
av. = 11.6
CG3 1 7.1036 9.0 6.7 24.8
2 7.254 9.2 6.9 24.1
av. = 24.4
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A.6.3 In vitro dissolution rates 
 
MilliQ water Phosphate buffer pH 6.5, 0.05M Citrate buffer pH 3, 0.05M
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time [min] brix
% of 
max brix
% of 
max brix
% of 
max brix
% of 
max brix
% of 
max brix
% of 
max brix
% of 
max brix
% of 
max brix
% of 
max
0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.8 0.0 0.8 0.0 1.1 0.0 1.3 0.0 1.3 0.0 0
1 1
2 0.8 0.0 1.3 5.6 1.6 10.4 2.6 14.3 4.3 30.3 7.4 87.2 2
3 3
4 4
5 0.3 4.4 0.8 0.0 10.3 87.6 7.4 87.2 5
6 1.6 17.8 1.9 23.9 10.6 93.0 6
7 2.8 22.5 7.1 82.2 7
8 8
10 10.4 88.6 10
14 11.6 100.0 14
15 0.2 2.9 15
16 16
17 17
18 2.6 29.0 4.3 54.0 1.0 2.6 4.6 42.7 8.3 97.9 11.3 100.0 8.3 100.0 18
19 19
20 20
27 1.2 5.1 27
28 28
29 5.9 57.3 8.3 97.9 29
33 33
37 1.5 9.0 37
45 3.9 43.4 6.5 81.7 45
48 1.8 12.8 7.7 77.5 48
49 49
50 50
58.2 8.6 87.6 51
54 54
55 55
60 60
67 0.2 2.9 2.9 26.3 67
71 71
80.6 9.7 100.0 75
79 79
82 3.5 34.6 82
85 4.6 51.2 7.2 90.5 85
91 91
92 92
97 4.3 44.9 97
102 102
108 9.7 100.0 108
120 5.3 57.7 120
135 1.4 135
140 140
150 6.8 76.9 150
175 0.8 11.8 175
180 180
191 7.5 85.9 191
210 210
217 1.3 19.1 217
233 8.6 100.0 233
235 235
258 1.6 23.5 258
276 9.1 276
295 295
336 9.4 336
390 7.4 82.4 7.9 99.2 390
430 2.6 38.2 430
453 9.8 100.0 453
458 458
468 468
1147 1147
1175 5.4 79.4 1175
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A.7 Coating PHZ granules 
A.7.1 Coating efficiency  
B1 (2.7% PVP)
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B1.1 12.0 24.0 60 3.6 15.0 13.0
B1.2 14.4 18.3 80 4.8 26.2 30.3
B1.3 17.4 15.1 60 3.6 23.8 30.9
B1.4 18.1 11.2 60 3.6 32.1 37.5
B1.5 21.3 7.3 60 3.6 49.3 45.1
B2 (1.3% PVP)
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B2.1 11.0 24.0 130 7.8 32.5 24.5
B2.2 12.2 20.0 60 3.6 18.0 24.6
B2.3 14.8 16.2 68 4.1 25.2 29.9
B2.4 17.2 12.4 62 3.7 30.0 34.5
B2.5 20.8 7 52 3.1 44.6 42.7
B3 (0.7% PVP)
Su
bb
at
ch
m
ea
su
re
d 
Eu
dr
a
gi
t %
 
[w
/w
]
m
at
e
ria
l i
n
 
th
e 
pa
n
 
[g]
sp
ra
yin
g 
so
lu
tio
n
 
[g]
Eu
dr
a
gi
t [g
]
 
E 
pe
r 
m
at
e
ria
l 
[g/
10
0g
]
Eu
dr
a
gi
t 
th
eo
re
tic
al
 
%
 
[w
/w
]
B3.1 10.0 25.3 60 3.6 14.2 12.5
B3.2 12.7 18.6 80 4.8 25.8 28.5
B3.3 16.5 16.3 60 3.6 22.1 28.5
B3.4 17.6 12.5 65 3.9 31.2 36.4
B3.5 18.6 8.3 66 4.0 47.7 44.2
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A.7.2 In vitro dissolution rates  
A.7.2.1 Small coated PHZ granules in different media 
Coated Granules in HCl 0.001M 
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54.2 123.77 437.703 437.703
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0 0.0000 0.0000 0 0.001 0.0 0.0
60 0.4988 5.7508 0.418 4.819 160.3745 36.6
255 0.5680 5.2630 1.245 11.536 384.2659 87.8
1035 0.3140 6.1340 0.625 12.209 406.7132 92.9
1335 0.5460 6.0340 1.085 11.991 399.4214 91.3
1635 0.3020 6.6301 0.541 11.877 395.6367
2235 0.3090 6.1150 0.663 13.121 437.0845 99.9
Coated Granules in Phosphate Buffer 
0
 
pr
od
u
ct
 
[m
g]
m
ed
iu
m
 
[g] co
n
ce
n
tra
t
io
n
 
pr
od
u
ct
 
[µg
/g
]
0 49.4 112.77 437.86 437.86
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0 0.0000 0.0000 0 0.000 0.0 0.0
60 0.6150 5.1420 0.295 2.466 81.94959 18.7
255 0.1970 3.7650 0.365 6.976 232.2587 53.0
1035 0.4470 6.0870 0.79 10.758 358.3262 81.8
1335 0.8650 6.3230 1.432 10.468 348.6557 79.6
1635 0.3400 6.4560 0.529 10.045 334.5592
2235 0.4520 6.1760 0.798 10.904 363.1882 82.9
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Coated Granules in Water
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0 0.0000 0.0000 0 0.002 0.0 0.0
60 1.1150 6.3380 0.181 1.029 34.02864 8.2
255 0.9120 5.8290 0.742 4.742 157.8151 37.8
1035 0.4690 6.0440 0.722 9.304 309.8803 74.3
1335 0.4530 6.4420 0.684 9.727 323.9664 77.7
1635 0.3070 6.4000 0.427 8.902 296.4543
2235 0.3920 6.0480 0.669 10.322 343.7905 82.4#VALUE!
PHZ as Powder in Water
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0 0.0000 0.0000 0 0.0 0.0 0.0
60 0.1330 6.4200 0.256 12.357 411.6431 106.3
255 0.4360 6.0100 0.87 11.992 399.481 103.1
1035 0.2720 5.9960 0.547 12.058 401.6711 103.7
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A.7.2.2 Larger coated PHZ granules in phosphate buffer. 
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15
PHZ Powder 147.572 256.688 109.116 60.1 0.698 14.388 0.645 13.296 464.521 550.487 84.4
B1.1 163.039 271.732 108.693 84.2 0.91 14.872 0.127 2.076 72.215 774.059 9.3
B2.1 158.108 266.019 107.911 80.5 0.937 14.67 0.106 1.660 57.670 745.429 7.7
B3.1 159.418 262.371 102.953 68.4 1.014 14.467 0.291 4.152 144.810 663.940 21.8
B1.2 159.325 265.162 105.837 75.2 1.033 14.983 0.109 1.581 54.922 710.022 7.7
B2.2 160.566 264.276 103.71 70.9 1.352 14.555 0.116 1.249 43.308 683.170 6.3
B3.2 159.332 267.118 107.786 67.6 1.836 15.021 0.16 1.309 45.413 626.776 7.2
B1.3 159.309 265.816 106.507 82.2 1.555 4.7357 0.461 1.404 48.733 771.185 6.3
B2.3 157.872 263.373 105.501 79.1 1.2751 4.8672 0.329 1.256 43.553 749.194 5.8
B3.3 162.088 265.558 103.47 77.3 1.3027 5.0672 0.509 1.980 68.870 746.519 9.2
B1.4 160.534 263.258 102.724 88.5 0.9312 3.9451 0.418 1.771 61.563 860.790 7.2
B2.4 160.082 263.17 103.088 78.6 1.0257 4.134 0.342 1.378 47.839 761.874 6.3
B3.4 (1) 158.734 265.181 106.447 61.1 1.2948 3.9847 0.481 1.480 51.401 573.665 9.0
B3.4 (2) 164.059 264.074 100.015 62.1 1.1189 4.0498 0.428 1.549 53.809 620.522 8.7
B3.4 (3) 159.022 260.921 101.899 59.7 1.1213 3.8593 0.437 1.504 52.233 585.531 8.9
B1.5 158.869 262.245 103.376 72 1.0769 4.0138 0.294 1.096 37.958 696.002 5.5
B2.5 158.919 258.09 99.171 78.7 1.2492 4.0383 0.438 1.416 49.151 792.950 6.2
B3.5 160.445 263.046 102.601 77.6 1.0063 4.7546 0.414 1.956 68.038 755.756 9.0
45
PHZ Powder 147.572 256.688 109.116 60.1 0.349 14.489 0.381 15.818 552.703 550.487 100.4
B1.1 163.039 271.732 108.693 84.2 1.046 12.431 0.364 4.326 150.898 774.059 19.5
B2.1 158.108 266.019 107.911 80.5 1.14 11.988 0.234 2.461 85.682 745.429 11.5
B3.1 159.418 262.371 102.953 68.4 1.122 12.848 0.597 6.836 238.673 663.940 35.9
B1.2 159.325 265.162 105.837 75.2 0.916 12.669 0.249 3.444 120.058 710.022 16.9
B2.2 160.566 264.276 103.71 70.9 1.111 11.645 0.333 3.490 121.684 683.170 17.8
B3.2 159.332 267.118 107.786 67.6 1.162 11.239 0.273 2.640 91.968 626.776 14.7
B1.3 159.309 265.816 106.507 82.2 0.918 12.165 0.248 3.286 114.553 771.185 14.9
B2.3 157.872 263.373 105.501 79.1 1.031 11.811 0.217 2.486 86.564 749.194 11.6
B3.3 162.088 265.558 103.47 77.3 0.978 10.923 0.318 3.552 123.827 746.519 16.6
B1.4 160.534 263.258 102.724 88.5 1.08 11.409 0.319 3.370 117.471 860.790 13.6
B2.4 160.082 263.17 103.088 78.6 1.185 8.184 0.346 2.390 83.195 761.874 10.9
B3.4 (1) 158.734 265.181 106.447 61.1 1.074 8.855 0.27 2.226 77.480 573.665 13.5
B3.4 (2) 164.059 264.074 100.015 62.1 1.185 8.651 0.35 2.555 88.984 620.522 14.3
B3.4 (3) 159.022 260.921 101.899 59.7 1.263 9.144 0.335 2.425 84.446 585.531 14.4
B1.5 158.869 262.245 103.376 72 1.327 8.221 0.369 2.286 79.574 696.002 11.4
B2.5 158.919 258.09 99.171 78.7 1.074 8.341 0.304 2.361 82.194 792.950 10.4
B3.5 160.445 263.046 102.601 77.6 0.986 8.349 0.34 2.879 100.306 755.756 13.3
116
PHZ Powder 147.572 256.688 109.116 60.1 0.427 14.561 0.464 15.823 552.897 550.487 100.4
B1.1 163.039 271.732 108.693 84.2 1.064 14.689 0.65 8.974 313.404 774.059 40.5
B2.1 158.108 266.019 107.911 80.5 1.282 14.438 0.612 6.892 240.636 745.429 32.3
B3.1 159.418 262.371 102.953 68.4 1.178 14.734 0.949 11.870 414.670 663.940 62.5
B1.2 159.325 265.162 105.837 75.2 1.179 14.636 0.467 5.797 202.346 710.022 28.5
B2.2 160.566 264.276 103.71 70.9 1.169 15.379 0.33 4.341 151.440 683.170 22.2
B3.2 159.332 267.118 107.786 67.6 1.172 14.87 0.408 5.177 180.643 626.776 28.8
B1.3 159.309 265.816 106.507 82.2 1.291 14.717 0.534 6.087 212.491 771.185 27.6
B2.3 157.872 263.373 105.501 79.1 1.174 13.691 0.4 4.665 162.746 749.194 21.7
B3.3 162.088 265.558 103.47 77.3 1.279 15.134 0.588 6.958 242.917 746.519 32.5
B1.4 160.534 263.258 102.724 88.5 1.005 10.156 0.655 6.619 231.080 860.790 26.8
B2.4 160.082 263.17 103.088 78.6 1.228 10.201 0.604 5.017 175.078 761.874 23.0
B3.4 (1) 158.734 265.181 106.447 61.1 1.075 10.605 0.447 4.410 153.829 573.665 26.8
B3.4 (2) 164.059 264.074 100.015 62.1 1.041 14.409 0.366 5.066 176.776 620.522 28.5
B3.4 (3) 159.022 260.921 101.899 59.7 1.084 10.358 0.467 4.462 155.670 585.531 26.6
B1.5 158.869 262.245 103.376 72 1.012 14.47 0.373 5.333 186.123 696.002 26.7
B2.5 158.919 258.09 99.171 78.7 1.272 11.404 0.56 5.021 175.190 792.950 22.1
B3.5 160.445 263.046 102.601 77.6 0.985 10.075 0.564 5.769 201.351 755.756 26.6
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176 PHZ Powder 147.572 256.688 109.116 60.1 0.761 13.795 0.9 16.315 570.088 550.487 103.6
B1.1 163.039 271.732 108.693 84.2 0.787 14.032 0.601 10.716 374.317 774.059 48.4
B2.1 158.108 266.019 107.911 80.5 0.888 14.35 0.569 9.195 321.146 745.429 43.1
B3.1 159.418 262.371 102.953 68.4 0.989 10.606 1.314 14.091 492.346 663.940 74.2
B1.2 159.325 265.162 105.837 75.2 0.965 11.023 0.656 7.493 261.649 710.022 36.9
B2.2 160.566 264.276 103.71 70.9 0.895 10.164 0.524 5.951 207.712 683.170 30.4
B3.2 159.332 267.118 107.786 67.6 1.067 10.384 0.729 7.095 247.706 626.776 39.5
B1.3 159.309 265.816 106.507 82.2 0.69 9.815 0.512 7.283 254.294 771.185 33.0
B2.3 157.872 263.373 105.501 79.1 0.739 10.288 0.443 6.167 215.281 749.194 28.7
B3.3 162.088 265.558 103.47 77.3 0.501 9.902 0.472 9.329 325.826 746.519 43.6
B1.4 160.534 263.258 102.724 88.5 0.461 10.231 0.403 8.944 312.364 860.790 36.3
B2.4 160.082 263.17 103.088 78.6 0.937 10.596 0.59 6.672 232.929 761.874 30.6
B3.4 (1) 158.734 265.181 106.447 61.1 0.867 10.454 0.508 6.125 213.815 573.665 37.3
B3.4 (2) 164.059 264.074 100.015 62.1 0.934 9.958 0.628 6.696 233.753 620.522 37.7
B3.4 (3) 159.022 260.921 101.899 59.7 0.888 10.331 0.51 5.933 207.103 585.531 35.4
B1.5 158.869 262.245 103.376 72 1.322 10.351 0.888 6.953 242.751 696.002 34.9
B2.5 158.919 258.09 99.171 78.7 1.028 11.02 0.579 6.207 216.664 792.950 27.3
B3.5 160.445 263.046 102.601 77.6 1.061 10.649 0.843 8.461 295.482 755.756 39.1
311
PHZ Powder 147.572 256.688 109.116 60.1 0.581 14.814 0.637 16.242 567.540 550.487 103.1
B1.1 163.039 271.732 108.693 84.2 0.685 14.664 0.731 15.649 546.802 774.059 70.6
B2.1 158.108 266.019 107.911 80.5 0.823 15.165 0.744 13.709 478.990 745.429 64.3
B3.1 159.418 262.371 102.953 68.4 0.752 14.524 0.851 16.436 574.331 663.940 86.5
B1.2 159.325 265.162 105.837 75.2 0.759 14.592 0.579 11.131 388.855 710.022 54.8
B2.2 160.566 264.276 103.71 70.9 0.713 14.418 0.468 9.464 330.542 683.170 48.4
B3.2 159.332 267.118 107.786 67.6 0.814 14.774 0.603 10.944 382.314 626.776 61.0
B1.3 159.309 265.816 106.507 82.2 0.957 10.092 1.116 11.769 411.137 771.185 53.3
B2.3 157.872 263.373 105.501 79.1 1.187 12.145 0.903 9.239 322.692 749.194 43.1
B3.3 162.088 265.558 103.47 77.3 1.047 10.561 1.373 13.849 483.886 746.519 64.8
B1.4 160.534 263.258 102.724 88.5 0.764 10.398 0.945 12.861 449.343 860.790 52.2
B2.4 160.082 263.17 103.088 78.6 1.059 10.302 1.041 10.127 353.731 761.874 46.4
B3.4 (1) 158.734 265.181 106.447 61.1 0.978 10.816 0.866 9.577 334.516 573.665 58.3
B3.4 (2) 164.059 264.074 100.015 62.1 0.989 11.688 0.883 10.435 364.514 620.522 58.7
B3.4 (3) 159.022 260.921 101.899 59.7 1.063 10.371 0.949 9.259 323.377 585.531 55.2
B1.5 158.869 262.245 103.376 72 1.054 11.289 0.974 10.432 364.404 696.002 52.4
B2.5 158.919 258.09 99.171 78.7 0.989 10.817 0.877 9.592 335.029 792.950 42.3
B3.5 160.445 263.046 102.601 77.6 1.101 11.128 1.187 11.997 419.126 755.756 55.5
1020
PHZ Powder 147.572 256.688 109.116 60.1 0.412 9.29 0.758 17.092 597.259 550.487 108.5
B1.1 163.039 271.732 108.693 84.2 0.316 9.77 0.659 20.375 712.048 774.059 92.0
B2.1 158.108 266.019 107.911 80.5 0.504 10.279 0.925 18.865 659.267 745.429 88.4
B3.1 159.418 262.371 102.953 68.4 0.659 9.862 1.173 17.554 613.422 663.940 92.4
B1.2 159.325 265.162 105.837 75.2 0.45 10.509 0.741 17.305 604.707 710.022 85.2
B2.2 160.566 264.276 103.71 70.9 0.512 10.363 0.824 16.678 582.789 683.170 85.3
B3.2 159.332 267.118 107.786 67.6 0.548 10.351 0.835 15.772 551.114 626.776 87.9
B1.3 159.309 265.816 106.507 82.2 0.3634 10.426 0.648 18.591 649.692 771.185 84.2
B2.3 157.872 263.373 105.501 79.1 0.3938 9.864 0.699 17.509 611.837 749.194 81.7
B3.3 162.088 265.558 103.47 77.3 0.4109 9.9049 0.748 18.031 630.092 746.519 84.4
B1.4 160.534 263.258 102.724 88.5 0.6932 10.327 1.301 19.381 677.307 860.790 78.7
B2.4 160.082 263.17 103.088 78.6 0.5897 10.12 1.022 17.539 612.889 761.874 80.4
B3.4 (1) 158.734 265.181 106.447 61.1 0.5926 9.9803 0.796 13.406 468.380 573.665 81.6
B3.4 (2) 164.059 264.074 100.015 62.1 0.4849 11.526 0.634 15.071 526.588 620.522 84.9
B3.4 (3) 159.022 260.921 101.899 59.7 0.5248 9.8392 0.737 13.818 482.777 585.531 82.5
B1.5 158.869 262.245 103.376 72 0.5789 10.031 0.905 15.682 547.955 696.002 78.7
B2.5 158.919 258.09 99.171 78.7 0.4984 9.9754 0.888 17.773 621.083 792.950 78.3
B3.5 160.445 263.046 102.601 77.6 0.4871 9.921 0.822 16.742 585.030 755.756 77.4
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A.7.2.3 Larger coated PHZ granules in HCl 
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PHZ 0 0.000 0.0 0.000 0.000 0.001 0.000 0.000 0.000 0.0
powder 15 93.636 72.7 0.580 9.738 1.329 22.313 756.364 775.808 97.5
64 93.636 72.7 0.435 9.936 1.057 24.143 818.395 775.808
128 93.636 72.7 0.469 9.738 1.106 22.964 778.425 775.808 100.3
281 93.636 72.7 0.412 10.271 0.912 22.736 770.682 775.808 99.3
B1.1 0 0.000 0.0 0.000 0.000 0.000 0.000 0.000 0.000 0.0
15 99.167 83.5 0.634 8.988 0.439 6.224 210.944 841.306 25.1
64 99.167 83.5 0.493 10.420 0.582 12.301 416.963 841.306 49.6
128 99.167 83.5 0.559 10.026 1.073 19.245 652.346 841.306 77.5
281 99.167 83.5 0.685 13.051 1.119 21.320 722.682 841.306 85.9
B1.2 0 0.000 0.0 0.000 0.000 0.001 0.000 0.000 0.000 0.0
15 97.455 89.7 0.507 9.787 0.231 4.459 151.134 919.578 16.4
64 97.455 89.7 0.435 9.819 0.836 18.871 639.656 919.578
128 97.455 89.7 0.586 9.753 1.076 17.908 607.035 919.578 66.0
281 97.455 89.7 0.630 13.735 1.063 23.175 785.572 919.578 85.4
B1.3 0 0.000 0.0 0.000 0.000 0.000 0.000 0.000 0.000 0.0
15 100.481 84.9 0.665 9.949 0.241 3.606 122.199 844.223 14.5
64 100.481 84.9 0.485 10.003 0.455 9.384 318.087 844.223 37.7
128 100.481 84.9 0.614 9.847 0.976 15.653 530.572 844.223 62.8
281 100.481 84.9 0.607 12.515 1.010 20.824 705.874 844.223 83.6
B1.4 0 0.000 0.0 0.000 0.000 0.002 0.000 0.000 0.000 0.0
15 102.271 81.0 0.570 10.158 0.095 1.693 57.366 791.387 7.2
64 102.271 81.0 0.499 9.778 0.411 8.054 272.980 791.387 34.5
128 102.271 81.0 0.713 10.075 0.990 13.989 474.184 791.387 59.9
281 102.271 81.0 0.499 12.485 0.739 18.490 626.749 791.387 79.2
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A.8 PHZ granules for in vivo trials 
A.8.1 Coating efficiency  
to
ta
l m
at
er
ia
l i
n
 
th
e 
pa
n
 
[g]
to
ta
l w
ei
gh
t 
in
cr
ea
se
 
[g]
m
at
er
ia
l c
o
lle
ct
ed
 
m
at
er
ia
l l
os
s 
[g]
re
cy
cle
d 
lo
st
 
m
at
er
ia
l [g
]
sp
ra
yin
 
so
lu
tio
n
 
ap
pl
ie
d 
[g]
Eu
dr
a
gi
t a
pp
lie
d 
[g]
170.1 0.0 0.0 0.0 0.0 0.0
171.8 1.7 0.6 53.0 3.2
174.0 3.9 0.5 44.0 5.8
176.1 6.0 1.2 62.2 9.6
178.7 8.6 0.8 56.6 12.9
181.3 11.2 0.8 0.4 67.7 17.0
183.6 13.5 58.7 20.5
184.6 14.5 31.1 22.4
188.2 18.1 63.1 26.2
190.2 20.1 1.2 0.5 39.2 28.5
192.5 22.4 72.6 32.9
196.8 26.7 0.6 90.7 38.3
201.0 30.9 0.5 99.0 44.3
total [g] 6.2 0.9
 
weight increase 
[% w/w]
total weight increase [g] 30.9 15.4
total weight increase 
considering recycled 
material [g] 36.2 17.5
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A.8.2 Measuring PHZ content  
 
Uncoated PHZ granules 0.7-1.0mm
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1 0.196 500 392 0.767 15.501 0.555 11.216 373.617 95.4
2 0.139 500 278 0.759 15.701 0.385 7.964 265.209 95.4
3 0.199 500 398 0.785 15.420 0.591 11.609 386.707 97.1
4 0.196 500 392 0.819 15.146 0.610 11.281 375.763 96.0
average= 96.0
st. dev.= 0.8
 
 
Coated PHZ granules 0.7-1.0mm
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1 0.207 500 415 0.750 14.790 0.470 9.268 308.680 74.4
2 0.197 500 394 0.828 14.789 0.499 8.913 296.823 75.3
3 0.198 500 396 0.854 15.230 0.476 8.489 282.695 71.4
4 0.202 500 404 0.807 15.169 0.465 8.741 291.083 72.1
average= 73.2
st. dev.= 1.8
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A.8.3 In vitro dissolution rates 
A.8.3.1 Phosphate buffer (0.05M, pH 6.5) - 100 mL-vials 
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0.5
1 85.3 996.6 1.54 6.277 0.06 0.245 8.734 85.584 10.2
2 82 996.1 1.427 6.209 0.065 0.283 10.101 82.314 12.3
3 78.4 990.1 1.319 6.741 0.044 0.225 8.031 79.178 10.1
1.38
1 85.3 996.6 1.357 3.205 0.252 0.595 21.256 85.584 24.8
2 82 996.1 1.224 3.685 0.183 0.551 19.677 82.314 23.9
3 78.4 990.1 1.429 3.493 0.22 0.538 19.206 79.178 24.3
2.63
1 85.3 996.6 1.151 5.126 0.208 0.926 33.083 85.584 38.7
2 82 996.1 1.325 6.284 0.179 0.849 30.319 82.314 36.8
3 78.4 990.1 1.321 6.214 0.175 0.823 29.400 79.178 37.1
4
1 85.3 996.6 1.242 6.049 0.246 1.198 41.535 85.584 48.5
2 82 996.1 1.43 5.801 0.276 1.120 38.791 82.314 47.1
3 78.4 990.1 1.056 5.589 0.207 1.096 37.950 79.178 47.9
7
1 85.3 996.6 1.336 6.605 0.321 1.587 56.678 85.584 66.2
2 82 996.1 1.31 5.518 0.352 1.483 52.954 82.314 64.3
3 78.4 990.1 1.352 5.869 0.326 1.415 50.541 79.178 63.8
20
1 85.3 996.6 1.041 6.831 0.284 1.864 66.557 85.584 77.8
2 82 996.1 1.381 6.08 0.397 1.748 62.423 82.314 75.8
3 78.4 990.1 1.173 6.751 0.295 1.698 60.636 79.178 76.6
30
1 85.3 996.6 1.173 6.849 0.306 1.787 63.811 85.584 74.6
2 82 996.1 1.331 6.968 0.335 1.754 62.635 82.314 76.1
3 78.4 990.1 1.185 12.212 0.165 1.700 60.729 79.178 76.7
50
1 85.3 996.6 1.25 7.266 0.308 1.790 63.941 85.584 74.7
2 82 996.1 1.146 6.757 0.299 1.763 62.963 82.314 76.5
3 78.4 990.1 1.157 6.546 0.298 1.686 60.214 79.178 76.0
75
1 85.3 996.6 5 5 1.78 1.780 63.571 85.584 74.3
2 82 996.1 5 5 1.754 1.754 62.643 82.314 76.1
3 78.4 990.1 5 5 1.678 1.678 59.929 79.178 75.7
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A.8.3.2 Phosphate buffer (0.05M, pH 6.5) - 1000 mL-vials 
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e 
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[%
 
w
/w
]
0.5
1 85.3 996.6 1.54 6.277 0.06 0.245 8.73423 85.58368 10.2
2 82 996.1 1.427 6.209 0.065 0.283 10.10074 82.31428 12.3
3 78.4 990.1 1.319 6.741 0.044 0.225 8.031084 79.17765 10.1
1.38
1 85.3 996.6 1.357 3.205 0.252 0.595 21.25645 85.58368 24.8
2 82 996.1 1.224 3.685 0.183 0.551 19.67656 82.31428 23.9
3 78.4 990.1 1.429 3.493 0.22 0.538 19.20574 79.17765 24.3
2.63
1 85.3 996.6 1.151 5.126 0.208 0.926 33.08328 85.58368 38.7
2 82 996.1 1.325 6.284 0.179 0.849 30.31903 82.31428 36.8
3 78.4 990.1 1.321 6.214 0.175 0.823 29.40008 79.17765 37.1
4
1 85.3 996.6 1.242 6.049 0.246 1.198 41.53535 85.58368 48.5
2 82 996.1 1.43 5.801 0.276 1.120 38.79138 82.31428 47.1
3 78.4 990.1 1.056 5.589 0.207 1.096 37.95004 79.17765 47.9
7
1 85.3 996.6 1.336 6.605 0.321 1.587 56.67785 85.58368 66.2
2 82 996.1 1.31 5.518 0.352 1.483 52.95354 82.31428 64.3
3 78.4 990.1 1.352 5.869 0.326 1.415 50.54137 79.17765 63.8
20
1 85.3 996.6 1.041 6.831 0.284 1.864 66.55702 85.58368 77.8
2 82 996.1 1.381 6.08 0.397 1.748 62.42268 82.31428 75.8
3 78.4 990.1 1.173 6.751 0.295 1.698 60.63649 79.17765 76.6
30
1 85.3 996.6 1.173 6.849 0.306 1.787 63.81056 85.58368 74.6
2 82 996.1 1.331 6.968 0.335 1.754 62.63497 82.31428 76.1
3 78.4 990.1 1.185 12.212 0.165 1.700 60.72875 79.17765 76.7
50
1 85.3 996.6 1.25 7.266 0.308 1.790 63.9408 85.58368 74.7
2 82 996.1 1.146 6.757 0.299 1.763 62.96257 82.31428 76.5
3 78.4 990.1 1.157 6.546 0.298 1.686 60.21447 79.17765 76.0
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A.8.3.3 HCl (10-3 M) -  100 ml vials 
tim
e 
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[%
 
w
/w
]
0.25
1 77.7 111.687 0.701 7.254 0.395 4.087 138.3217 695.2106 19.90
2 78.6 108.018 0.893 7.688 0.503 4.330 146.5566 727.1274 20.16
3 81.6 105.083 0.937 8.055 0.595 5.115 173.1515 775.9265 22.32
0.75
1 77.7 111.687 0.723 9.849 0.733 9.985 338.2449 695.2106 48.65
2 78.6 108.018 0.72 10.101 0.729 10.227 346.4496 727.1274 47.65
3 81.6 105.083 0.74 10.081 0.881 12.002 406.6047 775.9265 52.40
1.5
1 77.7 111.687 0.615 9.931 0.889 14.356 486.3913 695.2106 69.96
2 78.6 108.018 0.609 10.081 0.902 14.931 505.9029 727.1274 69.58
3 81.6 105.083 0.703 10.328 1.122 16.484 558.531 775.9265 71.98
2
1 77.7 111.687 0.675 10.026 1.053 15.641 529.9512 695.2106 76.23
2 78.6 108.018 0.896 10.342 1.403 16.194 548.7119 727.1274 75.46
3 81.6 105.083 0.794 11.19 1.271 17.912 606.9646 775.9265 78.22
3
1 77.7 111.687 0.807 10.573 1.285 16.836 570.46 695.2106 82.06
2 78.6 108.018 0.724 10.627 1.2 17.614 596.8411 727.1274 82.08
3 81.6 105.083 0.568 10.793 0.993 18.869 639.3813 775.9265 82.40
4
1 77.7 111.687 0.547 12.074 0.779 17.195 582.6429 695.2106 83.81
2 78.6 108.018 0.68 12.287 0.996 17.997 609.8251 727.1274 83.87
3 81.6 105.083 0.609 12.662 0.919 19.107 647.4696 775.9265 83.44
6
1 77.7 111.687 0.478 10.518 0.787 17.317 586.7896 695.2106 84.40
2 78.6 108.018 0.468 11.687 0.727 18.155 615.1798 727.1274 84.60
3 81.6 105.083 0.403 11.608 0.673 19.385 656.8838 775.9265 84.66
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A.9 Active rumen technology (ART) 
Device numbering: 
1-5: 15% bioactive payload 
6-10: 10% bioactive payload 
11-15: 5% bioactive payload 
16-20: 0% bioactive payload 
 
 
time [h] 0.00 time [h] 3.00Plunger position [mm] Plunger position [mm]
D
ev
ic
e
si
de
 
1
si
de
 
2 
a
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ra
ge
w
ei
gh
t o
f t
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ce
 
[g]
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m
e
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l]
D
ev
ic
e
si
de
 
1
si
de
 
2 
a
ve
ra
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m
e
 
ex
pe
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d 
[m
l]
ra
te
 
[m
l/d
ay
]
1 27.82 27.82 27.82 23.181 0.00 1 28.22 28.35 28.29 0.08
2 28.54 28.54 28.54 23.416 0.00 2 29.55 29.54 29.55 0.17
3 27.74 27.78 27.76 23.539 0.00 3 28.21 28.22 28.22 0.08
4 27.89 27.95 27.92 23.549 0.00 4 28.33 28.59 28.46 0.09
5 27.94 28.06 28.00 23.740 0.00 5 28.37 28.51 28.44 0.07
6 27.58 27.54 27.56 23.821 0.00 6 28.20 28.27 28.24 0.11
7 27.75 27.77 27.76 23.603 0.00 7 28.42 28.39 28.41 0.11
8 27.85 28.08 27.97 23.482 0.00 8 28.24 28.35 28.30 0.05
9 27.94 27.98 27.96 23.341 0.00 9 28.24 28.24 28.24 0.05
10 27.65 27.88 27.77 23.569 0.00 10 28.12 28.27 28.20 0.07
11 27.93 28.08 28.01 23.483 0.00 11 28.74 28.88 28.81 0.13
12 28.19 28.01 28.10 23.448 0.00 12 28.67 28.56 28.62 0.08
13 28.35 28.37 28.36 23.486 0.00 13 29.02 28.91 28.97 0.10
14 28.12 27.97 28.05 23.692 0.00 14 28.59 28.77 28.68 0.10
15 28.33 28.13 28.23 23.521 0.00 15 28.77 28.80 28.79 0.09
16 27.94 28.14 28.04 23.705 0.00 16 28.75 28.53 28.64 0.10
17 28.23 28.35 28.29 23.788 0.00 17 28.69 28.70 28.70 0.07
18 27.55 27.68 27.62 23.708 0.00 18 27.80 27.79 27.80 0.03
19 27.95 28.26 28.11 23.750 0.00 19 28.45 28.53 28.49 0.06
20 28.36 28.48 28.42 23.636 0.00 20 28.34 29.22 28.78 0.06
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time [h] 7.50Plunger position [mm]
D
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[g]
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t d
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[g]
1 30.47 30.52 30.50 0.44 22.756 0.425 2.469 2.524 0.055
2 31.70 31.75 31.73 0.53 22.921 0.495 2.470 2.533 0.063
3 30.49 30.81 30.65 0.48 23.100 0.439 2.435 2.495 0.060
4 30.60 30.69 30.65 0.45 23.106 0.443 2.433 2.514 0.081
5 30.47 30.52 30.50 0.41 23.368 0.372 2.472 2.513 0.041
6 30.34 30.45 30.40 0.47 23.369 0.452 2.432 2.474 0.042
7 30.71 30.66 30.69 0.48 23.134 0.469 2.436 2.490 0.054
8 30.81 30.59 30.70 0.45 23.073 0.409 2.431 2.470 0.039
9 30.43 30.31 30.37 0.40 22.950 0.391 2.445 2.482 0.037
10 30.67 30.80 30.74 0.49 23.121 0.448 2.438 2.488 0.050
11 30.97 31.22 31.10 0.51 22.987 0.496 2.441 2.485 0.044
12 30.83 30.70 30.77 0.44 23.040 0.408 2.937 2.967 0.030
13 31.32 31.04 31.18 0.47 23.017 0.469 2.442 2.481 0.039
14 31.13 31.22 31.18 0.52 23.179 0.513 2.435 2.486 0.051
15 30.90 30.85 30.88 0.44 23.093 0.428 2.435 2.474 0.039
16 31.13 30.96 31.05 0.50 23.247 0.458 2.416 2.445 0.029
17 31.07 31.00 31.04 0.45 23.325 0.463 2.432 2.461 0.029
18 30.18 30.43 30.31 0.44 23.258 0.450 2.474 2.501 0.027
19 30.80 31.05 30.93 0.47 23.279 0.471 2.441 2.470 0.029
20 31.64 31.60 31.62 0.53 23.105 0.531 2.437 2.470 0.033
 
 
 
time [h] 26.25Device NrPlunger position [mm]
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t d
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[g]
1 34.22 34.3 34.26 1.06 22.167 1.014 2.438 2.518 0.080
2 35.62 35.58 35.6 1.16 22.297 1.119 2.447 2.526 0.079
3 34.5 34.57 34.535 1.12 22.484 1.055 2.441 2.535 0.094
4 34.55 34.69 34.62 1.10 22.483 1.066 2.956 3.047 0.091
5 34.19 34.13 34.16 1.02 22.799 0.941 2.473 2.555 0.082
6 34.29 34.31 34.3 1.11 22.741 1.08 2.466 2.546 0.080
7 34.29 33.99 34.14 1.05 22.562 1.041 2.443 2.511 0.068
8 34.36 34.69 34.525 1.08 22.469 1.013 2.432 2.508 0.076
9 34.01 34.04 34.025 1.00 22.363 0.978 2.957 3.024 0.067
10 34.76 34.72 34.74 1.15 22.506 1.063 2.441 2.511 0.070
11 35.03 34.94 34.985 1.15 22.378 1.105 2.445 2.499 0.054
12 35.22 34.95 35.085 1.15 22.391 1.057 2.444 2.507 0.063
13 35.01 35.03 35.02 1.10 22.426 1.06 2.437 2.495 0.058
14 35.05 35.07 35.06 1.16 22.57 1.122 2.445 2.498 0.053
15 35.13 34.79 34.96 1.11 22.476 1.045 2.442 2.497 0.055
16 35.15 34.81 34.98 1.14 22.623 1.082 2.444 2.483 0.039
17 35.14 34.79 34.965 1.10 22.71 1.078 2.432 2.47 0.038
18 34.26 34.22 34.24 1.09 22.624 1.084 2.436 2.475 0.039
19 34.53 34.57 34.55 1.06 22.686 1.064 2.441 2.478 0.037
20 35.55 35.54 35.545 1.17 22.487 1.149 2.444 2.481 0.037
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time [h] 46.25Device NrPlunger position [mm]
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t d
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[g]
1 38.34 38.11 38.23 1.72 21.516 1.665 2.44 2.549 0.109
2 39.62 39.63 39.63 1.83 21.651 1.765 2.436 2.515 0.079
3 38.72 38.59 38.66 1.80 21.787 1.752 2.414 2.503 0.089
4 38.56 38.58 38.57 1.76 21.802 1.747 2.437 2.537 0.100
5 38.09 38.27 38.18 1.68 22.134 1.606 2.419 2.509 0.090
6 38.25 38.33 38.29 1.77 22.061 1.76 2.472 2.556 0.084
7 37.89 37.98 37.94 1.68 21.928 1.675 2.431 2.506 0.075
8 38.75 38.58 38.67 1.76 21.811 1.671 2.414 2.56 0.146
9 38.29 38.27 38.28 1.70 21.68 1.661 2.471 2.552 0.081
10 38.54 38.79 38.67 1.80 21.804 1.765 2.44 2.536 0.096
11 38.9 38.95 38.93 1.80 21.71 1.773 2.398 2.456 0.058
12 39.29 39.09 39.19 1.83 21.68 1.768 2.438 2.504 0.066
13 38.78 38.97 38.88 1.73 21.744 1.742 2.434 2.492 0.058
14 38.79 39.09 38.94 1.80 21.891 1.801 2.448 2.52 0.072
15 38.9 38.94 38.92 1.76 21.781 1.74 2.445 2.505 0.060
16 39.01 39.31 39.16 1.83 21.942 1.763 2.45 2.491 0.041
17 39.24 39.25 39.25 1.81 22.021 1.767 2.957 2.999 0.042
18 38.62 38.63 38.63 1.82 21.923 1.785 2.474 2.5189 0.045
19 38.6 38.43 38.52 1.72 22.044 1.706 2.419 2.457 0.038
20 39.64 39.65 39.65 1.85 21.817 1.819 2.47 2.51 0.040
 
 
time [h] 58.25Device NrPlunger position [mm]
De
vi
ce
sid
e 
1
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e
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w
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[g]
w
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gh
t d
ry
 
m
at
te
r 
[g]
1 44.73 44.66 44.70 2.78 20.413 2.768 2.448 2.613 0.165
2 46.11 46.35 46.23 2.92 20.607 2.809 2.447 2.6 0.153
3 45.65 45.84 45.75 2.97 20.6 2.939 2.434 2.596 0.162
4 45.72 45.4 45.56 2.91 20.695 2.854 2.954 3.065 0.111
5 45.12 44.89 45.01 2.80 21.03 2.71 2.442 2.544 0.102
6 45.81 45.59 45.70 2.99 20.874 2.947 2.413 2.568 0.155
7 44.51 44.52 44.52 2.76 20.829 2.774 2.958 3.08 0.122
8 45.19 45.22 45.21 2.84 20.703 2.779 2.936 3.065 0.129
9 44.87 45.32 45.10 2.83 20.536 2.805 2.955 3.104 0.149
10 46.02 46.15 46.09 3.02 20.603 2.966 2.953 3.122 0.169
11 45.96 46.11 46.04 2.97 20.518 2.965 2.442 2.551 0.109
12 46.53 46.52 46.53 3.04 20.456 2.992 2.922 3.08 0.158
13 45.88 45.94 45.91 2.89 20.63 2.856 2.448 2.547 0.099
14 45.52 45.9 45.71 2.91 20.805 2.887 2.419 2.528 0.109
15 46.25 46.41 46.33 2.98 20.594 2.927 2.439 2.564 0.125
16 46.4 46.43 46.42 3.03 20.732 2.973 2.43 2.503 0.073
17 46.65 46.57 46.61 3.02 20.801 2.987 2.927 3.03 0.103
18 46.08 46.07 46.08 3.04 20.689 3.019 2.45 2.528 0.078
19 44.98 45.5 45.24 2.83 20.883 2.867 2.445 2.604 0.159
20 46.94 47.25 47.10 3.08 20.598 3.038 2.442 2.521 0.079
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time [h] 58.25Device NrPlunger position [mm]
D
ev
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e
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[g]
w
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t d
ry
 
m
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r 
[g]
1 48.11 48.59 48.35 3.39 19.784 3.397 2.954 3.027 0.073
2 49.69 49.76 49.73 3.49 20.017 3.399 2.415 2.482 0.067
3 49.66 49.68 49.67 3.61 19.959 3.58 2.432 2.494 0.062
4 19.32 49.2 34.26 1.05 20.051 3.498 2.445 2.502 0.057
5 48.82 48.83 48.83 3.43 20.401 3.339 2.952 2.999 0.047
6 49.17 49.26 49.22 3.57 20.231 3.59 2.436 2.501 0.065
7 48.16 48.43 48.30 3.39 20.243 3.36 2.434 2.496 0.062
8 49.14 49.37 49.26 3.51 20.073 3.409 2.469 2.531 0.062
9 48.77 48.99 48.88 3.45 19.9 3.441 2.43 2.496 0.066
10 49.76 49.91 49.84 3.64 19.961 3.608 2.41 2.497 0.087
11 49.94 50.1 50.02 3.63 19.901 3.582 2.951 2.996 0.045
12 50.27 50.4 50.34 3.67 19.826 3.622 2.954 3.014 0.06
13 49.476 49.23 49.35 3.46 20.072 3.414 2.955 2.996 0.041
14 49.08 49.2 49.14 3.48 20.231 3.461 2.934 2.986 0.052
15 50.09 50.12 50.11 3.61 19.986 3.535 2.43 2.481 0.051
16 50.13 50.29 50.21 3.66 20.128 3.577 2.951 2.984 0.033
17 50.5 50.46 50.48 3.66 20.173 3.615 2.435 2.477 0.042
18 49.89 49.81 49.85 3.67 20.069 3.639 2.447 2.484 0.037
19 49.37 49.24 49.31 3.50 20.255 3.495 2.956 3.001 0.045
20 50.86 50.69 50.78 3.69 19.973 3.663 2.951 2.996 0.045
 
 
time [h] 70.25Device NrPlunge  position [mm]
D
ev
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t d
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[g]
1 51.92 51.84 51.88 3.97 19.288 3.893 2.924 2.978 0.054
2 52.64 52.57 52.61 3.97 19.579 3.837 2.435 2.477 0.042
3 53.01 53.2 53.11 4.18 19.438 4.101 2.41 2.474 0.064
4 52.7 52.69 52.70 4.09 19.543 4.006 2.44 2.482 0.042
5 52.19 51.81 52.00 3.96 19.921 3.819 2.466 2.512 0.046
6 52.75 52.77 52.76 4.16 19.735 4.086 2.413 2.453 0.04
7 51.9 51.48 51.69 3.95 19.747 3.856 2.925 2.97 0.045
8 52.71 52.63 52.67 4.07 19.538 3.944 2.934 2.982 0.048
9 51.9 52.29 52.10 3.98 19.407 3.934 2.953 2.987 0.034
10 53.54 53.45 53.50 4.24 19.446 4.123 2.971 3.028 0.057
11 53.31 53.32 53.32 4.17 19.375 4.108 2.956 3.005 0.049
12 54.23 54.22 54.23 4.31 19.238 4.21 2.943 2.999 0.056
13 53.19 52.96 53.08 4.08 19.526 3.96 2.966 3.019 0.053
14 52.49 52.59 52.54 4.04 19.686 4.006 2.96 3.011 0.051
15 53.7 53.7 53.70 4.20 19.421 4.1 2.961 3.012 0.051
16 53.64 53.59 53.62 4.22 19.542 4.163 3.002 3.047 0.045
17 53.62 53.65 53.64 4.18 19.598 4.19 2.955 3.001 0.046
18 53.62 53.66 53.64 4.29 19.475 4.233 2.962 3.019 0.057
19 49.37 52.62 51.00 3.77 19.714 4.036 2.997 3.038 0.041
20 50.86 54.69 52.78 4.02 19.4 4.236 2.956 2.995 0.039
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time [h] 83.75Device NrPlunge  position [mm]
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t d
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1 55.47 55.51 55.49 4.56 18.64 4.541 2.9958 3.0422 0.0465
2 56.37 56.38 56.38 4.59 18.941 4.475 2.9725 3.0118 0.0393
3 57.14 57.04 57.09 4.84 18.768 4.771 2.9898 3.0401 0.0503
4 56.49 56.79 56.64 4.74 18.9 4.649 2.9808 3.0162 0.0354
5 55.8 55.87 55.84 4.59 19.339 4.401 2.9653 3.0028 0.0375
6 56.55 56.52 56.54 4.78 19.093 4.728 3.0409 3.0887 0.0478
7 55.33 55.29 55.31 4.54 19.145 4.458 2.9751 3.0218 0.0468
8 56.76 56.63 56.70 4.74 18.885 4.597 3.0138 3.0579 0.0442
9 56.26 56.08 56.17 4.65 18.792 4.549 2.9832 3.0314 0.0482
10 57.39 57.26 57.33 4.87 18.786 4.783 2.9856 3.0360 0.0505
11 56.98 56.97 56.98 4.78 18.811 4.672 2.9623 3.0052 0.0429
12 58.32 58.05 58.19 4.96 18.627 4.821 2.9681 3.0230 0.0549
13 56.53 56.54 56.54 4.65 18.961 4.525 3.0037 3.0529 0.0492
14 56.13 56.41 56.27 4.65 19.103 4.589 2.9642 3.0082 0.0440
15 57.27 57.58 57.43 4.81 18.814 4.707 2.9819 3.0312 0.0493
16 57.73 57.74 57.74 4.90 18.935 4.77 2.9728 3.0091 0.0363
17 57.17 57.77 57.47 4.81 18.985 4.803 2.9469 2.9846 0.0378
18 58.29 57.77 58.03 5.02 18.834 4.874 2.9706 3.0144 0.0438
19 56.6 56.51 56.56 4.69 19.127 4.623 2.9505 2.9854 0.0349
20 58.26 58.28 58.27 4.92 18.799 4.837 3.0022 3.0366 0.0344
 
 
time [h] 94.25Device NrPlunger position [mm]
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t d
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1 58.18 57.73 57.96 4.97 18.293 4.888 2.940 2.9789 0.0389
2 58.59 58.75 58.67 4.97 18.592 4.824 2.968 3.0047 0.0367
3 59.7 60.17 59.94 5.31 18.364 5.175 2.997 3.0337 0.0367
4 59.4 59.39 59.40 5.19 18.509 5.040 2.999 3.0278 0.0288
5 58.45 58.13 58.29 4.99 18.951 4.789 3.000 3.0290 0.0290
6 59.12 59.23 59.18 5.21 18.709 5.112 2.948 3.0036 0.0556
7 57.59 57.69 57.64 4.93 18.757 4.846 2.965 3.0135 0.0485
8 59.52 59.5 59.51 5.20 18.480 5.002 2.945 2.9853 0.0403
9 58.96 58.75 58.86 5.09 18.425 4.916 2.980 3.0425 0.0625
10 60.22 59.93 60.08 5.33 18.380 5.189 3.000 3.0439 0.0439
11 59.46 59.27 59.37 5.17 18.448 5.035 3.005 3.0419 0.0369
12 60.96 60.97 60.97 5.42 18.187 5.261 2.943 2.9968 0.0538
13 59.11 59.07 59.09 5.07 18.558 4.928 2.970 3.0154 0.0454
14 58.82 59.02 58.92 5.09 18.696 4.996 2.973 3.0100 0.0370
15 60.13 60.16 60.15 5.26 18.382 5.139 2.957 3.0046 0.0476
16 60.37 60.41 60.39 5.33 18.491 5.214 3.003 3.0306 0.0276
17 60.48 60.55 60.52 5.31 18.539 5.249 3.000 3.0295 0.0295
18 60.4 60.36 60.38 5.40 18.395 5.313 2.948 2.9787 0.0307
19 59.46 59.33 59.40 5.16 18.676 5.074 3.003 3.0318 0.0288
20 60.85 61.05 60.95 5.36 18.358 5.278 2.954 2.9838 0.0298
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time [h] 106.25Device NrPlunge  position [mm]
D
ev
ic
e
si
de
 
1
si
de
 
2 
av
er
ag
e
vo
lu
m
e 
ex
pe
lle
d 
[m
l]
w
ei
gh
t o
f t
he
 
de
vi
ce
 
[g]
to
ta
l w
ei
gh
t l
os
s 
of
 
th
e 
de
vi
ce
 
[g]
w
ei
gh
t e
m
pt
y 
sa
m
pl
e 
vi
al
 
[g]
w
ei
gh
t s
am
pl
e 
vi
al
 
w
ith
 
dr
ie
d 
fo
rm
ul
at
io
n
 
[g]
w
ei
gh
t d
ry
 
m
at
te
r 
[g]
1 60.88 61.11 61.00 5.47 17.818 5.363 2.968 3.0370 0.0690
2 61.68 62.02 61.85 5.49 18.091 5.325 2.974 3.0116 0.0376
3 63.03 62.86 62.95 5.80 17.881 5.658 2.999 3.0272 0.0282
4 62.23 62.19 62.21 5.65 18.036 5.513 2.956 2.9989 0.0429
5 60.93 60.83 60.88 5.42 18.506 5.234 2.975 3.0197 0.0447
6 62.00 62.14 62.07 5.69 18.226 5.595 2.950 2.9932 0.0432
7 60.88 60.98 60.93 5.47 18.258 5.345 2.957 3.0223 0.0653
8 62.71 62.69 62.70 5.73 17.951 5.531 2.972 3.0483 0.0763
9 61.63 61.68 61.66 5.56 17.961 5.380 2.953 3.0303 0.0773
10 62.87 62.99 62.93 5.80 17.886 5.683 2.979 3.0252 0.0462
11 62.94 62.43 62.69 5.72 17.936 5.547 2.959 3.0188 0.0598
12 64.09 64.03 64.06 5.93 17.693 5.755 2.953 2.9969 0.0439
13 62.01 62.05 62.03 5.55 18.108 5.378 3.002 3.0449 0.0429
14 61.95 62.02 61.99 5.60 18.124 5.568 2.966 3.0145 0.0485
15 63.06 63.12 63.09 5.75 17.891 5.630 3.001 3.0477 0.0467
16 63.19 63.44 63.32 5.82 18.014 5.691 2.955 3.0024 0.0474
17 63.64 63.39 63.52 5.81 18.045 5.743 2.971 3.0018 0.0308
18 63.39 63.37 63.38 5.90 17.897 5.811 2.970 3.0020 0.0320
19 61.28 62.28 61.78 5.63 18.187 5.563 2.966 3.0020 0.0360
20 63.24 63.50 63.37 5.76 17.962 5.674 2.973 2.9946 0.0216
 
 
time [h] 119.75Device NrPlunge  position [mm]
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t d
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1 64.01 63.88 63.945 5.96 17.350 5.831 2.975 3.0271 0.0521
2 65.73 65.82 65.775 6.14 17.674 5.742 2.933 3.0270 0.0940
3 65.66 66.08 65.87 6.28 17.413 6.126 2.960 2.9773 0.0173
4 64.66 64.84 64.75 6.07 17.608 5.941 2.971 3.0028 0.0318
5 63.48 63.49 63.485 5.85 18.103 5.637 2.968 3.0050 0.0370
6 65.07 54.77 59.92 5.34 17.782 6.039 2.950 3.0009 0.0509
7 63.45 63.42 63.435 5.88 17.815 5.788 2.966 2.9911 0.0251
8 65.52 65.26 65.39 6.17 17.504 5.978 2.954 3.0173 0.0633
9 64.53 64.53 64.53 6.03 17.480 5.861 2.990 2.9947 0.0047
10 66.03 65.79 65.91 6.29 17.410 6.159 2.999 3.0455 0.0465
11 65.46 65.38 65.42 6.17 17.461 6.022 2.976 3.0436 0.0676
12 67.07 67.08 67.075 6.43 17.222 6.226 2.961 3.0337 0.0727
13 65.43 64.61 65.02 6.05 17.671 5.815 2.949 3.0124 0.0634
14 64.73 64.75 64.74 6.05 17.754 5.938 2.963 2.9961 0.0331
15 65.97 66.15 66.06 6.24 17.442 6.079 2.999 3.0026 0.0036
16 66.13 66.14 66.135 6.28 17.548 6.157 3.001 3.0383 0.0373
17 65.87 66.19 66.03 6.22 17.565 6.223 2.946 3.0332 0.0872
18 66.23 66.45 66.34 6.39 17.397 6.311 2.969 2.9840 0.0150
19 65.28 65.32 65.3 6.21 17.701 6.049 3.001 3.0059 0.0049
20 66.35 66.42 66.385 6.26 17.497 6.139 2.955 3.0313 0.0763
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time [h] 132.25Device NrPlunger position [mm]
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t d
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1 66.58 66.66 66.62 6.40 16.945 6.236 2.966 3.0050 0.0390
2 67.29 67.02 67.16 6.37 17.270 6.146 2.972 3.0076 0.0356
3 68.15 68.19 68.17 6.66 17.021 6.518 2.963 2.9881 0.0251
4 67.41 67.83 67.62 6.55 17.197 6.352 2.966 2.9956 0.0296
5 65.88 65.70 65.79 6.23 17.775 5.965 2.937 2.9645 0.0275
6 67.40 67.73 67.57 6.60 17.369 6.452 2.963 3.0001 0.0371
7 66.03 66.16 66.10 6.32 17.412 6.191 2.950 2.9847 0.0347
8 68.42 68.44 68.43 6.67 17.058 6.424 2.937 2.9778 0.0408
9 67.30 67.38 67.34 6.49 17.065 6.276 2.985 3.0324 0.0474
10 68.67 68.57 68.62 6.74 17.013 6.556 2.960 2.9872 0.0272
11 68.17 68.16 68.16 6.62 17.011 6.472 2.962 3.0097 0.0477
12 69.84 70.23 70.04 6.92 16.724 6.724 2.951 3.0154 0.0644
13 67.29 67.29 67.29 6.42 17.238 6.248 2.962 3.0137 0.0517
14 67.72 67.49 67.61 6.52 17.317 6.375 2.971 3.0133 0.0423
15 68.59 69.15 68.87 6.70 16.948 6.573 2.951 2.9943 0.0433
16 68.88 69.19 69.04 6.76 17.113 6.592 2.958 3.0006 0.0426
17 69.42 69.33 69.38 6.77 17.143 6.645 2.941 2.9711 0.0301
18 69.07 69.30 69.19 6.85 16.961 6.747 2.941 2.9714 0.0304
19 68.29 68.25 68.27 6.70 17.264 6.486 2.944 2.9695 0.0255
20 67.88 67.94 67.91 6.51 17.249 6.387 2.959 2.9726 0.0136
 
 
time [h] 146.75Device NrPlunge  position [mm]
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[g]
w
ei
gh
t e
m
pt
y 
sa
m
pl
e 
vi
al
 
[g]
w
ei
gh
t s
am
pl
e 
vi
al
 
w
ith
 
dr
ie
d 
fo
rm
u
la
tio
n
 
[g]
w
ei
gh
t d
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1 69.19 69.10 69.15 6.81 16.552 6.629 3.0043 3.0333 0.0290
2 69.57 69.40 69.49 6.75 16.901 6.515 2.9546 2.9851 0.0305
3 69.98 69.92 69.95 6.96 16.734 6.805 2.9760 2.9777 0.0017
4 69.15 69.23 69.19 6.81 16.927 6.622 2.9620 2.9831 0.0211
5 66.75 66.76 66.76 6.39 17.602 6.138 2.9734 2.9901 0.0167
6 70.04 70.21 70.13 7.02 17.966 5.855 2.9740 2.9993 0.0253
7 68.65 68.71 68.68 6.75 17.019 6.584 2.9710 2.9984 0.0274
8 71.10 71.04 71.07 7.11 16.620 6.862 2.9771 3.0131 0.0360
9 69.69 69.67 69.68 6.88 16.672 6.669 2.9500 2.9796 0.0296
10 71.00 70.81 70.91 7.11 16.613 6.956 2.9551 2.9828 0.0277
11 70.34 70.27 70.31 6.98 16.662 6.821 2.9481 2.9811 0.0330
12 72.51 72.58 72.55 7.33 16.353 7.095 3.0043 3.0403 0.0360
13 69.79 69.80 69.80 6.83 16.843 6.643 2.9761 3.0117 0.0356
14 70.33 70.24 70.29 6.97 16.952 6.740 3.0047 3.0602 0.0555
15 71.36 71.54 71.45 7.13 16.599 6.922 2.9743 3.0042 0.0299
16 71.53 71.41 71.47 7.16 16.695 7.010 2.9554 2.9794 0.0240
17 71.84 71.99 71.92 7.19 16.679 7.109 2.9639 2.9915 0.0276
18 71.85 72.10 71.98 7.31 16.519 7.189 2.9742 2.9986 0.0244
19 71.14 70.92 71.03 7.16 16.838 6.912 2.9748 2.9976 0.0228
20 69.58 69.59 69.59 6.79 16.984 6.652 2.9713 2.9881 0.0168
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time [h] 157.75Device NrPlunger position [mm]
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t d
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1 70.83 70.82 70.83 7.09 16.280 6.901 2.9760 2.9939 0.0179
2 70.88 70.95 70.92 6.99 16.676 6.740 2.9640 2.9813 0.0173
3 70.73 70.66 70.70 7.08 16.600 6.939 2.9439 2.9580 0.0141
4 70.09 70.08 70.09 6.95 16.805 6.744 2.9732 2.9814 0.0082
5 67.46 67.37 67.42 6.50 17.473 6.267 2.9759 2.9882 0.0123
6 71.72 71.61 71.67 7.27 16.692 7.129 2.9739 2.9923 0.0184
7 70.47 70.42 70.45 7.04 16.734 6.869 3.0042 3.0281 0.0239
8 72.91 72.89 72.90 7.41 16.334 7.148 2.9739 2.9937 0.0198
9 71.77 71.73 71.75 7.22 16.421 6.920 2.9486 2.9646 0.0160
10 72.43 72.64 72.54 7.38 16.392 7.177 2.9732 2.9861 0.0129
11 72.30 72.28 72.29 7.30 16.406 7.077 2.9558 2.9856 0.0298
12 74.70 74.57 74.64 7.67 16.406 7.042 2.9768 3.0092 0.0324
13 71.93 71.83 71.88 7.18 16.561 6.925 2.9737 3.0017 0.0280
14 72.17 72.12 72.15 7.27 16.651 7.041 3.0049 3.0423 0.0374
15 73.20 73.11 73.16 7.41 16.349 7.172 2.9588 2.9847 0.0259
16 73.12 73.26 73.19 7.45 16.434 7.271 2.9733 2.9898 0.0165
17 73.74 73.56 73.65 7.48 16.399 7.389 2.9755 2.9927 0.0172
18 73.59 73.97 73.78 7.61 16.238 7.470 2.9624 2.9791 0.0167
19 72.49 72.55 72.52 7.40 16.550 7.200 2.9563 2.9739 0.0176
20 70.71 70.51 70.61 6.96 16.856 6.780 2.9744 2.9807 0.0063
 
 
time [h] 171.75Device NrPlunge  position [mm]
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t d
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1 72.01 71.73 71.87 7.26 16.130 7.051 2.9743 2.9863 0.0120
2 72.10 71.94 72.02 7.17 16.510 6.906 2.9478 2.9565 0.0087
3 72.47 71.48 71.98 7.29 16.513 7.026 3.0040
4 70.84 70.66 70.75 7.06 16.667 6.882 2.9718 2.9807 0.0089
5 67.99 68.05 68.02 6.60 17.374 6.366 2.9547
6 73.44 73.40 73.42 7.56 16.416 7.405 2.9766 2.9946 0.0180
7 72.86 72.68 72.77 7.42 16.368 7.235 2.9492 2.9510 0.0018
8 74.93 75.01 74.97 7.75 16.018 7.464 2.9487 2.9801 0.0314
9 73.32 73.26 73.29 7.47 16.330 7.011 2.9473
10 73.76 73.61 73.69 7.57 16.253 7.316 2.9742 2.9830 0.0088
11 75.46 75.61 75.54 7.84 15.861 7.622 3.0038 3.0707 0.0669
12 77.34 77.26 77.30 8.11 15.594 7.854 2.9497 3.0092 0.0595
13 74.58 74.80 74.69 7.64 16.088 7.398 2.9754 3.0457 0.0703
14 74.75 74.99 74.87 7.72 16.228 7.464 2.9758 3.0315 0.0557
15 75.38 75.36 75.37 7.77 16.005 7.516 2.9490 2.9941 0.0451
16 75.58 75.45 75.52 7.83 16.062 7.643 2.9732 2.9927 0.0195
17 76.34 76.23 76.29 7.91 15.993 7.795 2.9498 2.9740 0.0242
18 76.38 76.40 76.39 8.04 15.801 7.907 2.9735 2.9989 0.0254
19 75.37 75.26 75.32 7.87 16.110 7.640 2.9747 2.9993 0.0246
20 72.41 75.37 73.89 7.50 16.542 7.094 3.0044 3.0253 0.0209
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time [h] 182.75Device NrPlunge  position [mm]
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t d
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1 73.22 72.87 73.05 7.46 2.9300 2.9902 0.0602
2 72.72 72.62 72.67 7.28 16.382 7.034 2.9625
3 71.85 71.57 71.71 7.25 16.466 7.073 2.9464
4 71.18 71.28 71.23 7.14 16.581 6.968 2.9744
5 68.24 68.25 68.25 6.64 17.314 6.426 2.9712
6 74.55 74.46 74.51 7.74 16.234 7.587 2.9757 2.9937 0.0180
7 74.15 74.13 74.14 7.65 16.116 7.487 3.0032 3.0152 0.0120
8 76.13 76.01 76.07 7.93 15.833 7.649 2.9738 2.9951 0.0213
9 74.66 74.55 74.61 7.69 15.971 7.370 2.9743 2.9986 0.0243
10 74.61 74.55 74.58 7.72 16.031 7.538 2.9739 2.9930 0.0191
11 76.48 76.61 76.55 8.00 15.716 7.767 2.9751 3.0208 0.0457
12 78.78 78.80 78.79 8.36 15.363 8.085 3.0062 3.0322 0.0260
13 76.42 76.38 76.40 7.92 15.772 7.714 2.9472 2.9926 0.0454
14 76.65 76.55 76.60 8.01 15.911 7.781 2.9735 3.0095 0.0360
15 77.49 77.67 77.58 8.14 15.618 7.903 2.9563 3.0124 0.0561
16 77.47 77.49 77.48 8.15 15.710 7.995 2.9743 2.9963 0.0220
17 78.39 78.37 78.38 8.26 15.658 8.130 2.9737 2.9882 0.0145
18 78.76 78.78 78.77 8.44 15.394 8.314 2.9555 2.9813 0.0258
19 77.43 77.44 77.44 8.22 15.767 7.983 2.9729 2.9971 0.0242
20 73.84 73.85 73.85 7.49 16.310 7.326 2.9643 2.9825 0.0182
 
 
time [h] 197.75Device NrPlunge  position [mm]
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ev
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de
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ce
 
[g]
w
ei
gh
t e
m
pt
y 
sa
m
pl
e 
vi
al
 
[g]
w
ei
gh
t s
am
pl
e 
vi
al
 
w
ith
 
dr
ie
d 
fo
rm
u
la
tio
n
 
[g]
w
ei
gh
t d
ry
 
m
at
te
r 
[g]
1
2
3
4
5
6 75.18 75.11 75.15 7.85 16.120 7.701
7 75.08 75.16 75.12 7.81 15.952 7.651
8 76.62 76.44 76.53 8.01 15.715 7.767
9 75.53 75.41 75.47 7.83 15.865 7.476
10 75.43 75.14 75.29 7.84 15.941 7.628
11 80.23 80.17 80.20 8.61 15.100 8.383 2.9636
12 80.90 81.04 80.97 8.72 15.012 8.436 2.9566
13 79.25 79.26 79.26 8.39 15.308 8.178 2.9503
14 79.05 78.89 78.97 8.40 15.530 8.162 2.9771
15 80.03 79.92 79.98 8.53 15.253 8.268 2.9660
16 79.95 80.37 80.16 8.59 15.310 8.395 2.9511
17 80.86 81.16 80.86 8.67 15.247 8.541 3.0028
18 81.27 81.37 81.32 8.86 15.020 8.688 3.0057
19 80.10 80.22 80.16 8.66 15.357 8.393 3.0032
20 76.48 76.33 76.41 7.91 15.907 7.729 2.9557
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time [h] 208.25Device NrPlunger position [mm]
D
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[g]
w
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m
pl
e 
via
l [g
]
w
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e 
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w
ith
 
dr
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d 
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u
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tio
n
 
[g]
w
ei
gh
t d
ry
 
m
a
tte
r 
[g]
1
2
3
4
5
6
7
8
9
10
11 80.59 80.36 80.48 8.65 2.9566 3.0583
12 81.04 81.28 81.16 8.75 2.9570 3.0172
13 79.66 79.38 79.52 8.44 2.9541 3.0137
14 79.69 79.56 79.63 8.51 2.9639 3.0314
15 80.43 80.53 80.48 8.62 2.9755 3.0164
16 80.89 80.76 80.83 8.70 2.9757 2.9710
17 81.74 81.53 81.64 8.80 2.9749 3.0265
18 82.03 82.30 82.17 9.00 2.9510 3.0247
19 80.75 80.99 80.87 8.78 2.9733 3.0243
20 77.26 77.21 77.24 8.05 2.9744 2.9774
 
 
time [h] 218.25Device NrPlunger position [mm]
D
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e
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[g]
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[g]
w
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gh
t d
ry
 
m
at
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r 
[g]
1
2
3
4
5
6
7
8
9
10
11 80.48 80.30 80.39 8.64 14.939 8.544
12 81.39 81.59 81.49 8.80 14.872 8.576
13 80.21 80.01 80.11 8.53 15.153 8.333
14 80.19 80.20 80.20 8.60 15.301 8.391
15 80.93 80.88 80.91 8.69 15.087 8.434
16 81.34 81.62 81.48 8.81 15.095 8.610
17 82.16 82.00 82.08 8.87 15.035 8.753
18 82.18 82.36 82.27 9.01 14.803 8.905
19 81.66 81.63 81.65 8.91 15.150 8.600
20 78.37 78.59 78.48 8.25 15.548 8.088
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time [h] 227.25Device NrPlunger position [mm]
D
ev
ic
e
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de
 
1
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2 
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[g]
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[g]
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e 
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al
 
w
ith
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ie
d 
fo
rm
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at
io
n
 
[g]
w
ei
gh
t d
ry
 
m
at
te
r 
[g]
1
2
3
4
5
6
7
8
9
10
11 80.70 80.54 80.62 8.68
12 81.51 81.63 81.57 8.82
13 80.51 80.48 80.50 8.60
14 80.68 80.61 80.65 8.67
15 81.00 81.04 81.02 8.71
16 81.85 82.10 81.98 8.89
17 82.14 82.23 82.19 8.89
18 82.33 82.28 82.31 9.02
19 81.90 82.01 81.96 8.96
20 79.27 79.13 79.20 8.37
 
